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1. INTRODUCTION 
 
1.1. ORAL DRUG DELIVERY SYSTEM         
  (Brahmankar D.M. and Jaiswal S.B., 2009; Robinson J.R. and Lee V.H.L., 2005) 
 Oral drug delivery has been known for decades as the most widely used route of 
administration among all the routes. Oral delivery of drugs is the most preferable route of 
drug delivery due to ease of administration, patient compliance and flexibility in 
formulation. Pharmaceutical product designed for oral delivery which are currently 
available in the market mostly immediate-release or conventional release, which 
maintains the drug concentration within the therapeutically effective range only, when 
administered several times a day. This results in a significant fluctuation of drug level in 
plasma. 
An ideal dosage regimen in the drug therapy of any disease is the one which 
immediately attains the desired therapeutic concentration of drug in plasma (or at site of 
action) and maintains it constant for the entire duration of treatment. This is possible 
through administration of conventional dosage form in a particular dose and at particular 
frequency. The frequency of administration or dosing interval of any drug depends upon 
its half-life or mean residence time (MRT) and its therapeutic index. In most cases, 
dosing interval is shorter than the half-life of the drug resulting in a number of limitations 
associated with such a conventional dosage form. 
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1.2. ORAL CONTROLLED DRUG DELIVERY SYSTEM                                          
                                           (Brahmankar D.M., 2009; Jain N. K., 2008) 
Oral controlled release dosage forms (CRDF) have been extensively used to 
improve therapy of many important medications. The design of oral controlled drug 
delivery systems (CDDS) should primarily be aimed at achieving more predictable and 
increased bioavailability of drugs. However, the developmental process is precluded by 
several physiological difficulties, such as inability to restrain and locate the CDDS within 
desired regions of gastrointestinal tract (GIT) due to the variable gastric emptying and 
motility. The variability may lead to unpredictable time for peak plasma levels and 
bioavailability. Therefore, the CRDF approaches has not been suitable for a variety of 
important drugs, characterized  by a narrow absorption window in the  upper part of the 
GIT, i.e. stomach and small intestine, which is due to relatively short transit time of the 
dosage form in these anatomical segments. Thus within a short period (less than 6 hours), 
the CRDF of such drugs leave the upper part of GIT and reaches to the non-absorbing 
distal segment, eventually resulting in a short absorption phase accompanied with lesser 
bioavailability. 
 Invariably, conventional dosage forms do not maintain the drug blood levels 
within the therapeutic range for an extended period of time. To achieve the same, a drug 
may be administered repeatedly using a fixed dosing interval. This causes a several 
potential problems like saw tooth kinetics characterized by large peaks and troughs in the 
drug concentration-time curve  
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Fig 1.1: A hypothetical plasma drug concentration-time profile from conventional 
multi dosing and an ideal controlled delivery formulation 
  The relatively brief gastric emptying time in humans normally averages 2 to 3 
hours. Through the major absorption zone (stomach or upper part of the intestine), which 
can result in incomplete drug release from the drug delivery system in a specific region of 
the GIT offers numerous advantages, especially to the drugs having narrow absorption 
window in GIT, primary absorption in the stomach stability problem in the intestine, poor 
solubility at alkaline P
H
 , local activity in the stomach and property to degrade in colon. 
Compounding the drugs with narrow absorption window enable an extended absorption 
phase of these drugs. 
  One of the most feasible approaches for achieving a prolonged and predictable 
drug delivery profiles in the GIT is to control the gastric residence time, using 
gastroretentive dosage forms (GRDF).GRDF are the drug delivery systems that are 
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designed to be retained in the stomach for a prolonged time and release their active 
materials and thereby enable sustained input of the drug to the upper part of the GIT. This 
technology has generated enormous attention over the last few decades owing to its 
potential retention in the upper GIT can greatly improve the oral delivery of some 
important drugs for which prolonged retention in the upper GIT can greatly improve their 
oral bioavailability and/or their therapeutic outcome. 
In the last three decades various attempts have been made to develop a novel and 
efficient gastro-retentive dosage forms which can retain in the stomach for an extended 
period of time in a predetermined manner. This can be achieved by improving scientific 
and technological advancement to overcome physiological problems like P
H 
of the 
stomach, motility and gastric emptying time by altering physiological and formulation 
variables. Many approaches are utilized in the development of gastric retention drug 
delivery systems viz., floating systems, swelling, expanding, high density, super porous 
hydro gels, bioadhesive, modified shape systems, ion exchange resin and by the 
simultaneous administration of pharmacological agents that delay gastric emptying. By 
utilizing one of these techniques it is possible to deliver drugs that have narrow 
absorption window. 
From the formulation and technological point of view, the floating drug delivery 
system (FDDS) is considerably easy and logical approach in the development of GRDF. 
Floating drug delivery system float on the gastric fluid only when it has density less than 
that of gastric fluids, i.e. <1 g/cm
3
. Usually, floating formulations are prepared from 
hydrophilic matrices that either have a density lower than one or their density drops 
below one after immersion in the gastric fluids owing to swelling. More sophisticated 
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devices are developed later and involved in the use of various film coating techniques, 
incorporation of a floating chamber that is filled with harmless gas, or a liquid that 
gasifies at body temperature. These systems are often called hydro-dynamically balanced 
system (HBS) as they can maintain low density and keep floating even after hydrating. 
This system provides several advantages as prolonged gastric retention of drugs, 
improves bioavailability, reduces drug wastage and improves solubility for drugs that are 
less soluble in an alkaline P
H
 environment and provides local drug delivery to the 
stomach and proximal small intestine. 
1.3. ANATOMY AND PHYSIOLOGY OF STOMACH    
                                                                     (Ross and Wilson;2006 )  
Stomach is an organ with capacity for storage and mixing. It is located just below 
the diaphragm in the epigastric and left hydrochondriac region of the abdomen. 
      The stomach is anatomically divided into three parts:  
 Fundus 
 Body 
 Pylorus (Or antrum) 
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Fig 1.2: It shows structure of stomach 
 
Stomach is made up of fundus and body regions. They are capable of displaying a 
large expansion to accommodate food without much increase in intragastric pressure. 
Stomach lining is devoid of villi and it consists of considerable number of gastric 
pits that contribute to storage capacity of the stomach. Ant rum region is responsible for 
the mixing and grinding of gastric content. There are two main secretions: mucus and 
acid, produced by specialized cell in stomach lining. Mucus is secreted by goblet cells 
and gastric acid by parietal cells (oxyntric) The Mucus spread and cover the rest of GI 
tract. Under fasting condition the stomach is a collapsed bag with a residual volume of   
50 ml and contains a small amount of gastric fluid (pH 1-3) and air. 
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 Physiology: 
 The physiology and disease state of stomach has a direct effect on design 
of controlled drug delivery system because drug is absorbed from and enters into 
site of action. Factors such as pH, nature and volume of gastric secretions and 
gastric mucosa play an important role in drug release and absorption.  
        Table 1.1: Table shows anatomical difference between different regions of the GIT 
 
 pH:  
 Environmental pH affects the performance of orally administered drugs. 
The pH of stomach in fasted condition is about 1.5 to 2 and in fed conditions 
it is usually 2 to 6. A large volume of water administered with oral dosage 
form changes the pH of stomach to pH of water initially. This change occurs 
because stomach does not have enough time to produce sufficient quantity of 
acid before emptying of liquid from the stomach.            
                                                                                                                                                 
Particulars Stomach 
Small 
intestine 
Large 
intestine 
Rectum 
pH range 1-3 5-7.5 7.9-8.0 7.5-8.0 
Length (cm) 20 285 110 20 
Diameter (cm) 15 2.5 5 2.5 
Surface area(sq.m) 0.1-0.2 200 0.15 0.02 
Blood flow(L/min) 0.15 1.0 0.02 - 
Transit time (hrs) 1-5 3-6 6-12 6-12 
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 Volume: 
The resting volume of stomach is about 25-52 ml. Gastric volume is 
important for dissolution of the dosage forms in-vivo. Meyer et al. conducted 
an experiment to study the effect of gastric fluid volume on absorption of 
controlled release theophylline dosage form in human beings. During this 
experiment they measured the gastric fluid volume of each subject. They 
estimated the mean gastric fluid volume in normal and achlorhydric subjects. 
The mean volume recovered by gastric aspiration over three consecutive, 15 
min. time periods was 61+ 51 ml in achlorhydric subjects and 98+38 ml in 
normal subjects. Thus, there is such a large volume difference in gastric 
secretions that would significantly affect in-vivo dissolution of drugs. 
 Gastric mucosa:  
  Simple columnar epithelial cells line the entire mucosal surface of the 
stomach. Mucus, parietal and peptic cells are present in the body of stomach. 
These cells are associated with different functions. The parietal cells secrete 
acid whereas the peptic cells secrete precursor for pepsin. The surface 
mucosal cells secrete the mucus and bicarbonate. They protect the stomach 
from digestion by pepsin and from the adverse effects of hydrochloric acid. 
As mucus has lubricating effect, it allows chyme to move freely through the 
digestive system. 
 Gastric secretion:      
Acids, pepsin, gastrin, mucus and some other enzymes are the secretions 
of   the stomach. Normal adults produce a basal secretion up to 60 ml with 
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approximately 4 milli mol of hydrogen ions every hour. Other potent 
stimulators of gastric acid are the hormones like gastrin, peptides, amino acids 
and gastric distention. 
 Liquid In fasted and fed conditions: 
  Volumes of liquids affect gastric emptying of liquids, larger the volume, 
faster the emptying. Gastric emptying of small volumes like 100 ml or less is 
governed by the MMC cycle whereas large volumes of liquids 200 ml or more 
are emptied out immediately after administration.  
 Effect of food on gastric secretion: 
Type of meal and its caloric content, volume, viscosity and co-
administered drugs affect gastric secretions and gastric emptying time. The 
rate of emptying primarily depends on caloric contents of the ingested meal. It 
does not differ for proteins, fats and carbohydrates as long as their caloric 
contents are the same.  
 Gastric motility:                                                                           (Jain N.K., 2008) 
The pattern series of motility is distinct in fasted and fed states. During the 
fasting state an inter digestive series of electrical events takes place, which cycle 
both through stomach and intestine every 2 to 3 hrs. This is called the 
interdigestive  
myoelectric cycle or migrating myoelectric cycle (MMC), which is divided into 
following 4 phases.  
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    Fig. 1.3: It shows the four phases of myoelectric cycle 
 Phase I (basal): Lasts for 30 to 60 minutes. Contractions can be 
characterized by a lack of secretary, electrical, and contractile activity. 
 Phase II (preburst): Lasts for 20 to 40 minutes. With intermittent action 
potential and contractions. 
 Phase III (burst): Lasts for 10 to 20 minutes. Includes intense and regular 
contractions. It is due to this wave that all undigested material is swept out 
of the stomach down to the small intestine. It is also known as 
housekeeper wave. 
 Phase IV: Lasts for 0 to 5 minutes. 
After the ingestion of mixed meal, the pattern of contractions changes from 
fasted to fed state. It comprises continuous contractions as in phase II of fasted 
state. These contractions result in reducing the size of food particles (<1mm), 
which are propelled toward pylorus. During fed state onset of MMC is delayed 
resulting in slowdown of gastric emptying rate. 
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 Gastric emptying:                                                                        (Jain N.K., 2008) 
 It can be anticipated that, depending upon the physiological state of 
subject and design of pharmaceutical formulation, the emptying  process last from 
a few minute to 12 hours. Furthermore the relatively brief gastric emptying time 
in humans which normally averages 2 to 3 hours through the major absorption 
zone (stomach or upper part of intestine). Particle size and feeding state strongly 
affect the residence time of particles in the stomach. Some other factors affecting 
gastric emptying are type of meal and its caloric content, volume, viscosity and 
co-administered drugs. The rate of gastric emptying primarily depends on the 
caloric contents of the ingested meal. It does not differ for proteins, fats, and 
carbohydrates as long as their caloric content is the same. Generally an increase in 
acidity, osmolarity and caloric value slows down gastric emptying. Stress 
increases gastric emptying rate whereas depression slows it down. Females have a 
slower gastric emptying rate than males. Age and obesity also effect gastric 
emptying 
Table. 1.2: Shows transit time of stomach and small intestine  
with different dosage forms 
DOSAGE 
FORMS 
TRANSIT TIME(HOURS) 
STOMACH SMALL INTESTINE TOTAL 
TABLETS 2.7 3.1 5.8 
PELLETS 1.2 3.4 4.6 
CAPSULES 0.8 3.2 4.0 
SOLUTION 0.3 4.1 4.4 
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 Factors affecting gastric emptying time:  
                                                                        (Vyas S., 2009; Bandyopadhyay A.K., 2008) 
 Volume: 
    The resting volume of stomach is about 25 to 52ml. This volume is 
important for dissolution of dosage forms. As the volume is large, emptying is 
faster. Gastric emptying of small volumes like 100ml or less is governed by MMC 
cycle where as large volumes of liquids like 200ml or more are emptied out 
immediately after administration. Fluids at body temperature leave the stomach 
more rapidly than either warmer or colder fluids. 
 Harmonal effects: 
  Stress condition increases gastric emptying rate where as depression slows 
down gastric emptying time. Generally females have slower gastric emptying rate 
than males. Age and obesity also affect gastric emptying.  
 Presence of food: 
  Gastric emptying time differs in fasted state and in fed state. The caloric 
value of food affects the gastric emptying time. 
 Gastric secretions: 
  Acids, pepsin, gastrin, mucus and other enzymes and other enzymes are 
the secretions of stomach. Normal adults produce a basal secretion upto 60ml 
with approximately 4 millimoles of hydrogen ions every hour.  
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 Factors affecting gastric residence time of dosage form: 
                                                                          (Vyas S., 2008; Bandyopadhyay A.K.,2008) 
 Density: 
 Gastric residence time increases if the density of the dosage form is less than 
the gastric contents (<1.004 gm/ml). 
Size and shape: 
      Small-size tablets leave the stomach during the digestive phase while the 
large size tablets are emptied during the housekeeping waves. 
 Fed or unfed state: 
  Under fasting conditions, the GI motility is characterized by periods of 
MMC that occurs every 1.5  to  2 hours. The MMC sweeps undigested  material 
from the stomach and if the timing of  administration of the formulations 
coincides with that of the MMC, the gastric residence time of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and gastric 
residence time is considerably longer. 
 Frequency of feed: 
  The gastric residence time can be increased by over 400 minutes when 
successive meals are given compared with a single meal due to the lower 
frequency of MMC. 
 Posture: 
Gastric residence time can vary between supine and upright ambulatory state 
of the patients 
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 Concomitant drug administration: 
 Anticholinergics like atropine and propentheline, opioids like codeine and 
prokinetic agents like metoclopromide and cisapride affects the GRT when 
administered together. 
 Biological factors: 
       Diabetes and crohn’s disease also affects gastric residence time. 
1.3.1. Formulation approaches for gastro retentive drug delivery system  
                                                                                                                    (Garg R., 2008) 
    There are several formulation approaches used for designing gastro retentive drug 
delivery systems. These include swelling and expanding system, which are retained in the 
gastric region due to their large size gained after swelling. Floating system is retained in 
the gastric region due to their floating ability on the gastric fluid. The floating system is 
further divided into single unit system such as floating tablets and multiparticulate 
systems such as floating microspheres, which offer more advantages as compared to 
single unit system. The floating system is further divided into effervescent and non-
effervescent floating system based on their mechanisms of floating. Bioadhesive systems 
adhere to the gastric mucosa due to which they are retained in the gastric region. High 
density systems are retained due to their increased density then the gastric fluid. Beside 
this, passage delaying food as well drugs can be administered simultaneously to retained 
the dosage form in the gastric region.  
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  The flowchart shows the various approaches used to retain the dosage forms in 
the gastric region. 
                                                          
                                                              GRDDS 
                                                                  ` 
         
 
Swelling and                    Floating system            Bioadhesive                 High-Density 
Expanding systems                                                   systems                          systems 
                                                       
                                                                              
Single unit systems                                                        Multiparticulate Systems 
         
           
Effervescent                       Non   Effervescent       Effervescent                    Non   Effervescent 
                                                                                 Microparticles                Waxy microparticles 
                                                                                 Microballons                  Alginate beads 
                                                                                 Pellets, beads                  Foam powder 
                                             low density polymer 
                                         (hydrophilic & hydrophobic) 
 
Gas generating excipients in gel forming polymers                
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 Swelling and expanding systems: 
         Swelling type dosage forms are such that after swallowing , these products 
swell to an extent that prevents there exit from the stomach through the pylorus . As a 
result, the dosage form is retained in the stomach for a long period of time. These systems 
may be referred to as 'plug type ' systems since they exhibit tendency to remain lodged at 
the pyloric sphincter.  
 Floating system (low density approach) 
           These systems are also known as hydro–dynamically balanced systems. 
(HBS/FDDS) they have a bulk density lower than gastric fluid, i.e. their bulk density is 
less than one. The specific gravity of gastric fluid is approximately 1.004 to1.010 gm/cm³ 
and thus the FDDS remains buoyant in the stomach without affecting the gastric 
emptying rate for a prolonged period of time. While the system is floating on gastric 
contents the drug is released slowly at a desired rate from the system. After the release of 
the drug the residual system is emptied from the stomach. 
 Bioadhesive system: 
           They are used to localize a delivery device within the lumen and cavity of 
the body to enhance the drug absorption process in a site-specific manner. It makes use of 
bioadhesive polymers. These polymers tend to form hydrogen and electrostatic bonds at 
the mucus polymer boundary. 
 High density systems: 
         High density formulations include coated pellets that have density greater 
than that of stomach contents. (>1.004g/cm³) This is accomplished by coating the drug 
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with heavy inert materials such as barium sulfate, titanium dioxide, iron powder or oxide. 
The weighed pellet can be covered with a diffusion-controlling polymer membrane. 
 Modified shape systems: 
         These are non-disintegrating geometric shapes molded from silastic 
elastomer or extruded from polyethylene blends which extend the gastric residence time 
depending on size and shape of the dosage form. 
1.3.1.1. Use of other delayed gastric emptying device: 
  It includes feeding of ingestible polymers or fatty acid salts that change the 
motility pattern of the stomach to a fed state, thereby decreasing the gastric emptying rate 
and permitting considerable prolongation of drug release. 
 Osmotic regulated system: 
           It is comprised of an osmotic pressure controlled drug delivery device and 
an inflatable floating support in a bioerodable capsule. In the stomach the capsule quickly 
disintegrates to release the intragastric osmotically  controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid 
that gasifies at body temperature to inflate the bag. The osmotic pressure controlled drug 
delivery consists of two components are as drug reservoir compartment and osmotically 
active compartment. 
 Incorporation of passage delaying food agents: 
  The food excipients like fatty acids, e.g. salts of myristic acid change and 
modify the pattern of the stomach to a fed state, there by decreasing gastric emptying rate 
and permitting considerable prolongation of release. The delay in the gastric emptying 
after meals rich in fats is largely caused by saturated fatty acids with chain of C10 to C14. 
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 Ion exchange resin: 
  A coated ion exchange resin bead formulation has been shown to have 
gastric retentive properties, which was loaded with bicarbonates. Ion exchange resins are 
loaded with bicarbonate and a negatively charged drug is bound to the resin, resultant 
beads were then encapsulated in a semi-permeable membrane to overcome the rapid loss 
of carbon dioxide. Upon arrival in the acidic environment of the stomach and exchange 
of chloride and bicarbonate ions take place. As a result of this reaction carbon dioxide 
was released and trapped in a membrane thereby carrying beads towards the top of gastric 
content and producing a floating layer of resin beads in contrast the uncoated beads 
which will sink quickly 
 
1.4. TECHNOLOGICAL DEVELOPMENT IN FDDS    
                                                 (Bandyopadhyay A.K., 2008; Patil J.M., et al., 2006) 
Based on the mechanism of buoyancy, two distinctly different types, i.e. non-
effervescent and effervescent systems have been utilized in the development of FDDS.  
A.  Effervescent FDDS:  
 Effervescent system utilize matrices prepared with swellable polymers such as 
methocel or polysaccharides e.g., chitosan and effervescent components, e.g., sodium 
bicarbonate and citric or tartaric acid or matrices containing chambers of liquid that 
gasify at body temperature.  The matrices are fabricated so that upon arrival in the 
stomach, carbon dioxide is liberated by the acidity of the gastric contents and is 
entrapped in the gellified hydrocolloid. This produces an upward motion of dosage form 
and maintains its buoyancy. 
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a. Multiple-unit oral floating drug delivery system: 
Recently a multiple–unit type of floating pill, which generates carbon dioxide gas, 
has been developed. The system consisted of sustained–release pills as seeds surrounded 
by double layers. The inner layer an effervescent layer containing both sodium 
bicarbonate and tartaric acid. The outer layer was a swellable membrane layer containing 
mainly polyvinyl acetate and purified shellac. Moreover, the effervescent layer was 
divided into two sub layers the sodium bicarbonate was contained in the inner sub layer 
and tartaric acid was in the outer layer.  
 
Fig 1.4: It shows multiple unit oral floating drug delivery system 
When the swollen pills are formed, like balloons, they have a density much lower 
than 1.004 gm/cm
3
. The reaction was due to carbon dioxide generated by neutralization 
in the inner effervescent layer with the diffusion of water through the outer swellable 
membrane layer.  
             A floating system utilizing ion-exchange resins has been developed. The system 
consisted of resin beads, which were loaded with bicarbonate and a negatively charged 
drug that was bound to the resin. The resultant beads were then encapsulated in a semi 
permeable membrane to overcome rapid loss of carbon dioxide. Upon arrival in the acidic 
environment of stomach, an exchange of chloride and bicarbonate ion takes place, as it is 
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expected. As result of this reaction, carbon dioxide was released and trapped in the 
membrane, thereby, carrying beads toward the top of gastric contents and producing a 
floating layer of resin beads. In contrast, the uncoated beads sink quickly. Radioactivity 
measurement by scintigraphy showed that gastric residence was substantially prolonged, 
compared with a control, when the system was given after a light, mainly liquid meal.  
 
 
 
 
 
 
 
 
            Fig 1.5:  It shows mechanism of effervescent drug delivery system 
 
           Furthermore, the system was capable of slow release of drug, a Property which 
widens the scope of such floating system for SR preparation of drugs possessing negative 
charge since they can be easily bound to the resin in combination with bicarbonate ions. 
Two patents on FDDS issued to the Alza Corporation disclosed drug delivery devices for 
the controlled and continuous administration of medicinal agents. Following figure shows 
mechanism of floating of effervescent drug delivery system. 
b. Inflatable gastrointestinal drug delivery system:                 
 The residence time of the drug delivery device in the stomach can also be 
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sustained by incorporation of an inflatable chamber, which contains a liquid, e.g., ether 
that gasifies at body temperature to cause the chamber to float in the stomach. 
 
 
 
 
 
 
 
 
 
             Fig 1.6: It shows inflatable gastrointestinal drug delivery device 
 
c. Intragastric osmotically controlled drug delivery system:              
 It is comprised of an osmotic pressure controlled drug delivery and an inflatable 
floating support in a bio-erodible capsule. When the drug delivery device reaches the site 
of drug administration e.g. the stomach, the capsule quickly disintegrates to release the 
intragastric osmotically controlled drug delivery device. The inflatable floating support is 
made from a deformable hollow polymeric bag that contains a liquid that gasifies at body 
temperature to inflate the bag. Although single unit floating dosage forms have been 
extensively studied, these single unit dosage forms have the disadvantage of a release all 
or nothing emptying process while the multiple unit particulate system pass through the 
GIT to avoid the vagaries of gastric emptying and thus, release the drug more uniformly. 
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 The uniform distribution of these multiple unit dosage forms along the GIT could result 
in more reproducible drug absorption and reduced risk of local irritation; this gave birth 
to oral controlled drug delivery and led to development of gastro-retentive floating 
microspheres. 
 
 
 
 
 
 
 
 
 
             Fig 1.7: It shows intragasric osmotically controlled drug delivery device. 
 
B.   NON-EFFERVESCENT FDDS 
                Floating microsphere are gastro-retentive delivery systems based on non-
effervescent approach.  Gastro-retentive floating microspheres are low density systems 
that have sufficient buoyancy to float over gastric contents and remain in stomach for 
prolonged period.  As the system floats over gastric contents, the drug is released slowly 
at desired rate resulting increased gastric retention with reduced fluctuations in plasma 
drug concentration.  Hollow microspheres are prepared by solvent diffusion and 
evaporation methods to create the hollow inner core.   
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a. Hydro dynamically balanced intragastric delivery system  
The hydro dynamically balanced gastrointestinal drug delivery systems, in either 
capsule or tablet form, is designed to prolong GI residence time in an area of the GI tract 
to maximize drug reaching its absorption site in solution state and hence, ready for 
absorption. It is prepared by incorporating a high level (20-75% w/w) of one or more gel-
forming hydrocolloids e.g. hydroxyl ethylcellulose, hydroxypropyl cellulose, hydroxyl 
propyl methyl cellulose and sodium carboxy methyl cellulose into the formulation and 
then compressing these granules into a tablets.  
On contact with gastric fluid the hydrocolloid in this intragatric floating device 
start to become hydrated and forms a colloid gel barrier around its surface with thickness 
growing with time. This barrier controls the rate of solvent penetration into the device 
and the rate of drug release from the device (Fig. 1.10). It maintains a bulk density of less 
than 1 and thus, remains buoyant in the gastric fluid inside the stomach for up to 6 hours.  
 
 
Fig 1.8: It shows working principle of hydrodynamically balance system 
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b. Bilayer tablet:                    
 A bilayer tablet can be prepared to contain one immediate–release layer and one 
sustained–release layer. After the initial dose is delivered by the immediate release layer, 
the sustained layer absorbs the gastric fluid and forms a colloidal gel barrier on its 
surface.  This produces a bulk density less than that of the gastric fluid and release 
remains buoyant in the stomach for extended period of time.  
 
   
 
 
 
 
 
 
 
Fig 1.9: It shows intragastric floating bilayer tablet 
 
c. Intragastric floating gastrointestinal drug delivery system: 
               A gastrointestinal drug delivery system can be made to float in the stomach by 
incorporating a floatation chamber, which may be a vacuum or filled with a harmless gas. 
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            Fig 1.10: It shows intra-gastric floating drug delivery device 
 
 A drug reservoir is encapsulated inside a micro-porous compartment with 
apertures along its top and bottom walls. The peripheral walls of the drug reservoir 
compartment are completely sealed to prevent any direct contact of the stomach mucosal 
surface with the un-dissolved drug. In the stomach the floatation chamber causes the 
gastrointestinal drug delivery system to float in the gastric fluids. Fluids enter through the 
apertures, dissolve the drug and carry and drug solute out of the drug delivery system for 
continuous transport to the intestine for absorption. The other two walls in contact with 
the fluid are sealed so that undissolved drug remains therein. 
 
1.5. RECENT ADVANCES                                                            
1.5.1. Floating multi-layer coated tablets:  
           Floating  multi-layer coated tablets were designed based on gas formation. The 
system  consists of a drug -containing core tablet coated with a protective layer 
(hydroxypropyl methylcellulose), a gas forming layer (sodium bicarbonate) and a gas-
entrapped membrane respectively. The acrylic polymers Eudragit and ethyl cellulose 
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were suitable film for the system, and was chosen as gas-entrapped membrane due to its 
high flexibility and high water permeability.  
1.5.2. Raft System 
          A gel–forming solution (e.g. sodium alginate solution containing carbonates or 
bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2 bubbles 
on contact with gastric fluid. Formulations also typically contain antacids such as 
aluminum hydroxide or calcium carbonate to reduce gastric acidity.  
1.5.3. Magnetic system 
           This system is based on a simple idea that the dosage form contains a small 
internal magnet and a magnet placed on the abdomen over the position of stomach. The 
internal tablet guided by the oesophagus with an external magnet. These systems seem to 
work, the external magnet must be positioned with a degree of precision that might 
compromise patient compliance. 
Criteria for selection of drug candidate for FDDS: 
1) Drugs required to exert local therapeutic action in the stomach e.g. 
Misoprostol, 5-Flurouracil, Antacids and anti-helicobacter pylori agents and 
certain enzymes. 
2) Drugs exhibiting site-specific absorption in the stomach or upper part of small 
intestine. e.g. Atenolol, Levodopa, P-Aminobenzoic acid, piretanide, 
Salbutamol. 
3) Drugs insoluble in intestinial fluids ( acid soluble basic drugs). e.g. 
Chlordiazepoxide, Chlorpheneramine, Cinnarzine,Diazepam, Diltiazem, 
Metaprolol, Propranolol, Verapamil. 
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4) Drugs with variable bioavailability. e.g. Sotalol hydrochloride and Levodopa. 
5) Drugs unstable in lower part of GI tract. e.g. Captopril. 
 
1.6. LIMITATIONS OF FDDS    
                                            (Mayavanshi A.V. and Gajjar S.S., 2008) 
 The major limitation of floating system is requirement of a sufficient high level of 
fluids in the stomach for the drug delivery to float. However this limitation can be 
overcome by coating the dosage form with the help of bio-adhesive polymers that 
easily adhere to the mucosal lining of the stomach. 
 Floating system is not feasible for those drugs that have solubility or stability 
problem in gastric fluids.  
  Drugs which are irritant to gastric mucosa cannot be applicable to GRDFs, 
floating system.  
 The residence time in the stomach depends upon the digestive state. Hence FDDS 
should be administered after the meal. 
 The ability of drug to remain in the stomach depends upon the subject being 
positioned upright.  
 The dosage form should be administered with a minimum of glass full of water 
(250 ml). 
 
1.7. ADVANTAGES OF FDDS  
                            (Garg R. and Gupta G.D., 2008; Mayavanshi A.V, Gajjar S.S.2008) 
 It is advantageous for drugs absorbed through the stomach, for e.g. Riboflavin. 
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 It is not restricted to medicaments, which are absorbed from stomach, since it has 
been found that these are equally efficacious with medicaments which are 
absorbed from the intestine.  
 It is advantageous for drugs meant for local action in the stomach, for e.g. 
antacids, antiulcer drugs. 
 It reduces fluctuations in circulating blood level of drug as shown by the 
conventional dosage form. 
 It shows more uniform levels of drug in plasma. 
 It releases drug slowly and for prolonged period of time and hence reduces dosing 
frequency.  
 It increases patient compliance as the dosing frequency is reduced.  
 The dissolved drug gets available for absorption in the small intestine after 
emptying of the stomach contents. It is therefore expected that a drug will be fully 
absorbed from the floating dosage forms if it remains in the solution. 
 Site specific drug delivery. 
 Retention of the drug in the GRDF at the stomach minimizes the amount of drug 
that reaches the colon, hence minimizes adverse activity at the colon.  
 
1.8. APPLICATIONS OF FLOATING DRUG DELIVERY SYSTEMS              
                                (Bandyopadhyay A.K., 2008; Mayavanshi A.V, Gajjar S.S.,2008) 
 Floating drug delivery offers several applications for drugs having poor 
bioavailability because of the narrow absorption window in the upper part of the 
gastrointestinal tract.  
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 Sustained Drug Delivery 
HBS systems can remain in the stomach for long periods and hence can 
release the drug over a prolonged period of time. The problem of short gastric 
residence time encountered with an oral CR formulation hence can be overcome with 
these systems. These systems have a bulk density of 1 as a result of which they can 
float on the gastric contents.  
The sustained release floating capsules of nicardipine hydrochloride compared 
with commercially available MICARD capsules using rabbits. Plasma concentration 
time curves showed a longer duration for administration (16 hours) in the sustained 
release floating capsules as compared with conventional MICARD capsules (8 
hours).  
 Site-Specific Drug Delivery 
These systems are particularly advantageous for drugs that are specifically 
absorbed from stomach or the proximal part of the small intestine, eg, furosemide.  
It has been reported that a monolithic floating dosage form with prolonged 
gastric residence time was developed and the bioavailability was increased. AUC 
obtained with the floating tablets was approximately 1.8 times those of conventional 
furosemide tablets.  
 Absorption Enhancement 
Drugs that have poor bioavailability because of site specific absorption from 
the upper part of the gastrointestinal tract are potential candidates to be formulated as 
floating drug delivery systems, thereby maximizing their absorption.  
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A significant increase in the bioavailability of floating dosage forms (42.9%) 
could be achieved as compared with commercially available LASIX tablets (33.4%) 
and enteric coated LASIX-long product. 
Marketed preparations of FDDS:                                                             (Garg R., 2008) 
     
               Table1.3: Marketed preparations of floating drug delivery system 
S. No. Product Active ingredients 
1 Madopar Levodopa & Benserazide 
2 Valrelease Diazepam 
3 Topalkan Aluminium magnesium 
4 Almagate Flacoat Antacid 
5 Liquid Gavison Alginic acid & bicarbonate 
6 Conviron Ferrous sulphate 
7 Cifran OD Ciprofloxacin 
8 Cytocheck Misoprostol 
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2. LITERATURE SURVEY 
 
2.1. Literature Review: 
1. Ajit.K et al., (2009) design bilayer regioselective floating tablets of atenolol and 
lovastatin to give immediate release of lovastatin and sustained release of 
atenolol. Bilayer floating tablets comprised two layers, i.e immediate release and 
controlled release layers. The immediate release layer comprised sodium starch 
glycollate as a super disintegrant and the sustained release layer comprised 
HPMC K100M and xanthan gum as the release retarding polymers. Sodium 
bicarbonate was used as a gas generating agent. Direct compression method was 
used for formulation of the bilayer tablets. Accelerated stability studies were 
carried out on the prepared tablets in accordance with ICH guidelines. All 
formulations floated for more than 12 h. More than 90% of lovastatin was 
released within 30 min. Diffusion exponents (n) were determined for all the 
formulations (0.53-0.59). The release of atenolol was found to follow a mixed 
pattern of Korsmeyer-Peppas, Hixson- Crowell and zero order release models. 
The optimized formulation was found to be buoyant for 8 h in stomach. 
Therefore, biphasic drug release pattern was successfully achieved through the 
formulation of floating bilayer tablets in this study. 
2. Anand.P et al., (2009) highlighted  a novel gastro retentive controlled release 
drug delivery system of verapamil HCl was formulated in an effort to increase the 
gastric retention time of the dosage form and to control drug release. 
Hydroxypropylmethylcellulose (HPMC), carbopol, and xanthan gum were 
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incorporated for gelforming properties. Buoyancy was achieved by adding an 
effervescent mixture of sodium bicarbonate and anhydrous citric acid. In vitro 
drug release studies were performed, and drug release kinetics was evaluated 
using the linear regression method. 
3. Arora.S et al., (2005) The recent development of FDDS including the 
physiological and formulation variables affecting gastric retention, approaches to 
design single unit and multiple unit floating system, and their classification and 
formulation aspects are covered in detail. These systems are useful to several 
problems encountered during the development of dosage form. 
4. Basak.S.C et al., (2004) performed floating tablets of Ciprofloxacin for 
prolongation of gastric residence time, leading to an increase in drug 
bioavailability and sustained action. In-vitro drug release study of these tablets 
indicated controlled sustain drug release for Ciprofloxacin and 80 to 89% release 
at the end of the 8
 
hours. 
5. Baumgartner.S et al., (2000) described the matrix-floating tablet incorporating 
high dose of freely soluble drug. The formulation containing 54.7% of drug, 
HPMC K4 M, Avicel PH 101 and a gas-generating agent had given the best 
results. It required 30 seconds to become buoyant. In-vivo experiments with 
fasted state in beagle dogs revealed prolonged gastric residence time. On 
radiographic images taken after 30 minutes of administration, the tablet was 
observed in animal stomach and the next image taken at 1 hr showed that the 
tablet had altered its position and turned around. The comparison of gastric 
motility and stomach emptying between humans and dogs showed no big 
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difference hence it was speculated that the experimentally proven increased 
gastric residence time in dogs than humans. 
6. Brahma N. Singh et al., (2000):the future potential for oral controlled drug 
delivery was discussed and also added that technological advancements have been 
made in the research and development of rate-controlled oral drug delivery 
systems by overcoming physiological adversities, such as GRT, GET. 
7. Chandira.M et al., (2009) described that floating tablets of Diltiazem 
hydrochloride by direct compression technique using hydrophilic polymers like 
HPMC k4M, HPMC K15M and hydrophobic polymers like ethyl cellulose as 
matrix material in various quantities . It was concluded that F6 is the best 
formulation. 
8. Dalavi V.V et al., (2009) expressed that gastroretentive drug delivery system of 
an antiretroviral agent of Zidovudine to achieve the objective, 3×3 factorial design 
were chosen. In this design amount of HPMC K4M (X1) and gas generating 
agents (X2) were selected as independent variable. The time required for 50% 
drug release t50% (Y1) was selected as dependent variable. The derived 
polynomial equations for t50%were verified by two check point formulations. The 
results of factorial design showed that factor X1 and X2 significantly affect the 
studied dependent variables. The formulation with good floating time (24hrs) and 
the percent drug release (98.05) emerged as optimal. 
9. Dave B.S et al., (2004)  explained the floating tablet of ranitidine hydrochloride 
by using guar gum, xanthan gum and hydroxylpropyl methylcellulose, Sodium 
bicarbonate was incorporated as gas generating agent. It is prepared by direct 
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compression method and in-vitro study done into 0.1 N HCl as dissolution 
medium. Drug release was calculated by Higuchi and Peppas models. 
10. Dhawale S.C et al., (2009) had developed and evaluated floating drug delivery 
system of Acyclovir. Gastric floating drug delivery was employed to develop 
controlled release preparation. Sodium bicarbonte as gas generating agent 
dispersed in a hydrogel matrix. The matrix was a mixture of HPMC K4M, HPMC 
K100M and xanthan gum. 
11. Ganesh S et al., (2008) characterized the controlled release matrix tablets of 
zidovudine using hydrophilic HPMC K4 M or carbopol 934 alone or in 
combination with hydrophobic ethyl cellulose. The in-vitro drug release shows 
that formulation of HPMC K4 M or carbopol 934 with ethyl cellulose sustain the 
drug release for nearly 12 hours. 
12. Garg.R et al., (2009) had prepared and evaluated floating tablets of silymarin as a 
model drug for prolongation of gastric residence time. Tablets were formulated by 
various materials like HPMC K4M, HPMC K15,Psyllium husk, Crosspovidone 
and gas generating agents like sodium bicarbonate and citric acid. The kinetics 
was found to follow both the higuchi and Korsermeyer-peppas equation. The 
floating tablets may be used in clinic for prolonged drug release for at least 24 
hours. 
13. Hoffman.A et al., (2003) Expandable gastroretentive dosage forms (GRDFs) 
have been designed for the past 3 decades. They were originally created for 
possible veterinary use, but later the design was modified for enhanced drug 
therapy in humans. These GRDFs are easily swallowed and reach a significantly 
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larger size in the stomach due to swelling or unfolding processes that prolong 
their gastric retention time (GRT). Positive results were obtained in preclinical 
and clinical studies evaluating GRT of expandable GRDFs. 
14. Jaimini.M et al., (2007)  formulated & evaluated floating tablets of Famotidine 
which were prepared by effervescent approach using two different grades of 
Methocel K100 and K15M. The tablets with Methocel K100 were found to float 
for longer duration as compared with formulations containing Methocel K15M. 
The drug release from the tablets was sufficiently sustained and non-Fickian 
transport of the drug from tablets was confirmed. 
15. J M Patil et al., (2005): discussed that several approaches are currently utilized in 
the prolongation of the GRT, including FDDS, swelling and expanding systems, 
polymeric bioadhesive systems, high density systems and other delayed gastric 
emptying devices. 
16. Kim H.K  et al., (2000) has studied the scientific and technological advancements 
have been made in the research and development of rate-controlled oral drug 
delivery systems by overcoming physiological adversities, such as short gastric 
residence times (GRT) and unpredicta  ble gastric emptying times (GET). Several 
approaches are currently utilized in the prolongation of the GRT, including 
floating drug delivery systems (FDDS), also known as hydrodynamically 
balanced systems (HBS), swelling and expanding systems, polymeric bioadhesive 
systems. 
17. Kishan.V et al., (2009) developed Floating matrix tablets of norfloxacin to 
prolong gastric residence time, leading to an increase in drug bioavailability. 
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Tablets were prepared by the wet granulation technique, using polymers such as 
hydroxypropyl methylcellulose (HPMC K4M, HPMC K100M) and xanthan gum. 
18. Mahesh Chavanpatil., et al., (2005): A new strategy is proposed for the 
development of gastroretentive dosage forms for Ofloxacin preferably once daily. 
The design was based on sustained release form. It was found that in vitro drug 
release rate increased with increased amount of crospovidone due to the increased 
water uptake, and hence increased driving force for drug release. 
19. Mayavanshi A.v et al., (2008) floating drug delivery system to increase gastric 
retention of drug: a review. Article studied the floating or hydrodynamically 
controlled drug delivery system are useful in gastric retention. 
20. Mina Ibrahim Tadros et al., (2010): selected ciprofloxacin hydrochloride which 
had a short elimination half-life, a narrow absorption window and is mainly 
absorbed in proximal areas of GIT. The purpose of this study was to develop a 
gastroretentive controlled release drug delivery system with swelling, floating, 
and adhesive properties using HPMC K15, Na alginate as polymers. 
21. Prajapati.S.T et al., (2009) developed gastric floating matrix tablet of        
Domperidone.  Box-Behnken design was employed in formulating gastric floating 
drug delivery system using three polymers HPMC (K4M), Carbopol 934P, 
Sodium alginate as independent variables. HPMC loading was found to be 
significant for floating properties. No significant effect of Sodium alginate on 
floating properties was observed but it was important for gel formation. The 
quadratic mathematical model developed could be used to predict formulations 
with desired release and floating properties. 
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22. Prakash. R et al.,  (2009) had formulated and optimized the floating drug 
delivery system containing cephalexin using 23 factorial designs. Floating tablets 
were prepared by direct compression method incorporating HPMC K4M,xanthan 
gum, guar gum, sodium bicarbonate and tartaric acid as gas generating agent. The 
influence of independent variables like, polymer ratio, polymer type and tartaric 
acid on floating lag time and cephalexin release profile were studied. 
23. Rajesh. K et al.,  (2009) formulated floating tablets of Ranitidine hydrochloride 
for prolongation of gastric residence time. Tablets of Ranitidine hydrochloride 
prepared by wet granulation technique using hydrophilic polymers like HPMC 
K100 and HPMC K 15M. It was found that the best formulation RT8 was having 
the floating lag time 120 seconds and showed 98.4% drug release at the end of 24 
hours. 
24. RajiniKanth.P.S et al,. (2009) fabricated  floating beads of clarithromycin for 
prolongation of gastric residence time, leading to an increase in drug 
bioavailability and sustained action. The beads were prepared by ionotopic 
gelation method against Helicobacter pylori. 
25. Rajput.G et al., (2009) reported the floating tablets of Metformin HCl using an 
effervescent approach for gastro retentive drug delivery system. Floating tablets 
were prepared using HPMC K100M and HPMC K4M polymers for their gel 
forming properties. It was concluded that polymer viscosity had major influence 
on drug release from hydrophilic matrix tablets as well as on floating lag time. As 
the viscosity increased drug release rate decreased. 
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26. Sable.V et al., (2010) formulation and evaluation of floating dosage forms: An 
overview. Floating dosage forms can be prepared as tablets, capsules, beads by 
incorporating suitable excipients as well by adding certain gas generating agent 
gives the buoyancy to the dosage form in gastric fluid. 
27. Sauzet. C et al., (2009) had formulated different technologies intended for gastro 
retentive dosage delivery were investigated and patented. The aim of this study 
was to develop an innovative floating gastro retentive dosage form (GRDF). The 
developed technology induces a low-density dosage form containing high active 
pharmaceutical ingredient (API) concentration by using a hydrophobic dusty 
powder excipient under specific conditions. The new dosage form was obtained 
by state of the artwet granulation manufacturing process. An apparatus was 
developed to measure the apparent density of floating tablet. The GRDF was 
characterized for apparent density, buoyancy, porosity and dissolution using in 
vitro experimentations. 
28. Sishu, N.Guptha et al., (2007): presented the investigation concerns in the 
development and evaluation of single unit floating tablets of 5-flurouracil, after 
oral administration which prolonged the gastric residence time, increased the drug 
bioavailability and targets the stomach cancer. 
29. Shishu., et al., (2009) urbanized  floating beads of 5-Flurouracil for prolongation 
of gastric residence time, leading to an increase in drug bioavailability and 
sustained action. The beads were prepared by dispersing 5-FU together with 
calcium carbonate into a mixture of Na-alginate and HPMC solution and then 
dripping the dispersion into an acidified solution of calcium carbonate. The 
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multiple beads was found to reduce tumor incidence in mice 74%, while the 
conventional tablet reduces tumor incidence in mice only 25%. 
30. Shweta Arora, et al., (2005): explained that recent developments of FDDS 
including the physiological and formulation variables affecting gastric retention, 
approaches to design single-unit and multiple unit floating systems and their 
classification and formulation aspects in detail. 
31. Thakkar V.T et al., (2008)   evaluated the levofloxacin hemihydrate floating 
formulations (F1-F9). Selection of optimized batch was done by model dependent 
approach and novel mathematical approach. F1-F9 batches were prepared by 
direct compression method using Gelucire 43/01 (hydrophobic) and 
hydroxypropyl methylcellulose (hydrophilic) polymer in different ratios. The 
floating tablets were evaluated for uniformity of weight, hardness, friability, drug 
content, in vitro buoyancy and in vitro release studies. Various models were used 
to estimate kinetics of drug release. 
32. Veepabrahma K et al. (2009)  discussed floating tablets of Norfloxacin as a 
model drug for prolongation of gastric residence time, leading to an increase in 
drug bioavailability. Tablets were prepared by wet granulation technique. The 
best formulation F4 was selected based on In-vitro characteristics and was used in 
vivo radiographic studies by incorporating BaSO4 
33. Viral F. Patil et al., (2006): This describes the development of an intragastric 
drug delivery system of cefuroxime anxetil. The 32 full factorial design was 
employed to evaluate contribution of HPMC K4M, HPMC K100 and SLS on 
drug release from HPMC matrices. It was found that polymer blend and SLS 
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significantly affect the time required for 50% of drug release, % drug release at 12 
hrs. 
34. Vishal G.K  et al., (2010)  explained that Floating tablet of Furosemide (FUR) by 
direct compression technique. Furosemide was chosen as model drug because it is 
slightly soluble in water and poorly absorb from lower intestine. PEG- 6000 is 
used as carrier agent for increasing solubility of Furosemide in water. 
Hydroxypropyl methylcellulose, sodium bicarbonate and carbopol were used as 
matrixing agent, gas generating agent and floating agent respectively. 
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2.2. DRUG PROFILE 
 
(http:// www .google.com; http:// www.rxlist; Indian Pharmacopoeia, 2007) 
Ofloxacin: 
Ofloxacin is a broad spectrum antibiotic that is active against both gram positive 
and gram negative. 
1. Molecular structure: 
 
(±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7oxo-7H-pyrido[1,2,3-
de]-1,4-benzoxazine-6-carboxylic acid 
2. Empirical formula       :    C18H20FN3O4 
3. Mol. Weight                 :    361.3 dalton 
4. Category                       :    Board spectrum antibiotic 
5. CAS Registry No.        :    82419-36-1 
6. Physical state               :    Solid off-white to pale yellow crystalline powder 
7. Melting Point               :    250-257 ˚C 
8. Odor                              :    Odorless 
9. Solubility                     :    Soluble in glacial acetic acid, slightly soluble in methanol, 
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                                            methylene chloride and water 
10.  Half life                       :     5-8 hours. 
11.  Synonyms                   :    (Zanocin, Travid) 
12. Pharmacology:                                                                                                                                                                                         
       Ofloxacin is a quinolone/fluoroquinolones antibiotic. Ofloxacin is bactericidal 
and its mode of action depends on blocking of bacterial DNA gyrase, which allows the 
untwisting required replicating one DNA double helix into two. Notably the drug has 100 
times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-
spectrum antibiotic that is active both Gram-positive and Gram-negative bacteria.                                          
13. Mode of action: 
        Ofloxacin is a broad-spectrum antibiotic that is active against both Gram- positive 
and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II 
topoisomerase, and topoisomerase IV, which is an enzyme necessary to separate 
replicated DNA, thereby inhibiting cell division. The fluroquinolones interfere with DNA 
replication by inhibiting the enzyme complex called DNA gyrase. This can also affect 
mammalian cells replication. In particular, some congeners of this drug family display 
high activity not only against bacterial topoisomerases, but also against eukaryotic 
topoisomerases and are toxic to cultured mammalian cells and in-vivo tumor models. 
Although the quinolone is highly toxic to mammalian cells in culture, its mechanism of 
cytotoxic action is not known, Quinolones induced DNA damage was first reported in 
1986. 
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14. Pharmacokinetic parameters: 
Parameters                                                Values
 
pKa                                   :                          6.00 
Partition coefficient           :                          High 
Oral absorption                 :                          98% 
Plasma half-life                  :                          5-8 hr 
Volume of distribution      :                          1.8 ±0.3 (liters/kg) 
Volume protein binding     :                          32% 
Biotransformation              :                          Hepatic 
15. Adverse Effects: 
       Nauesea, vomiting, abdominal pain, diarrhea, headache, insomnia, hallucinations, 
leucopenia and eoisnophilia, vaginitis, dysgeusia, tendon damage and rupture, anorexia, 
tremor, photosensitivity, hypersensitivity reactions discontinue if psychiatric, 
neurological or hypersensitivity reactions discontinue if psychiatric, neurological or 
hypersensitivity reactions occur. Potentially Fatal, Anaphylaxis, rarely seizures. 
16. Therapeutic uses: 
 Treatment of bacterial infections. 
 Acute bacterial exacerbations of chronic bronchitis. 
 Community-acquired Pneumonia. 
 Uncomlicated skin and skin structure infections. 
 Nongonococcal urethritis and cervicitis. 
 Mixed infections of urethra and cervix. 
 Acute pelvic inflammatory diseases. 
Intragastric drug delivery system of Ofloxacin                                         Literature Survey           
Adhiparasakthi college of pharmacy, Melmaruvathur.   44 
 
 Uncomplicated cystitis. 
 Complicated urinary tract infections. 
 Acute, Uncomplicated urethral and cervical gonorrhea. 
17.  Drug Interactions: 
                                   Table 2.1: Drug interactions 
Drugs Interactions 
Acenocoumarol The quinolone increases the anticoagulant effect 
Aluminium Formation of non-absorbable complexes 
Anisidione The quinolone increases the anticoagulant effect 
Bismuth Formation of non-absorbable complexes 
Calcium Formation of non-absorbable complexes 
Dicumarol The quinolone increase the anticoagulant effect 
Dihydroquinidine barbiturate Increased risk of cardiotoxicity and arrhythmias 
Foscarnet Increased risk of convulsions 
Iron Formation of non-absorbable complexes 
Magnesium Formation of non-absorbable complexes 
Magnesium oxide Formation of non-absorbable complexes 
Quinidine Increased risk of cardiotoxicity and  arrhythmias 
Quinidine barbiturate Increased risk of cardiotoxicity and arrhythmias 
Sucralfate Formation of non-absorbable complexes 
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18. Dosage administration: 
              The usual dose of Ofloxacin tablets is 200mg to 400mg orally 12hrs. 
19. Storage conditions: 
             Ofloxacin should be stored at room temperature, protect from sunlight. 
20. Contraindication: 
1. Ofloxacin is now considered to be contraindicated for the treatment of certain     
sexually transmitted diseases by some experts due to bacterial resistance 
    2. Ofloxacin is also considered to be contraindicated with 
 Pediatric population 
 Pregnancy 
 Nursing mothers 
 Patients with psychiatric illness  
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2.3. POLYMERS PROFILE 
 
2.3.1. HYPROMELLOSE (HYDROXYPROPYL METHYLCELLULOSE)                                                   
                                                                                                     (Rowe R.C., et al., 2003)                                                                  
A. Nonproprietary Names: 
BP: Hypromellose                                  JP: Hydroxypropylmethylcellulose                    
PhEur: Hypromellosum                         USP: Hypromellose 
B. Synonyms: 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
Tylopur. 
C. Chemical Name and CAS Registry Number: 
Cellulose hydroxypropyl methyl ether [9004-65-3] 
D. Molecular Weight: 
Molecular weight is approximately 10 000–1 500 000.  
E. Structural Formula: 
 
Where R is H, CH3, or CH3CH (OH) CH2 
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F. Functional Category: 
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent;suspending agent; tablet binder; viscosity-increasing agent. 
G. Applications in Pharmaceutical Formulation or Technology: 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in film-
coating, and as matrix for use in extended-release tablet formulations.  High-viscosity 
grades may be used to retard the release of drugs from a matrix at levels of 10–80% w/w 
in tablets and capsules. Lower-viscosity grades are used in aqueous film-coating 
solutions, while higher-viscosity grades are used with organic solvents.  
H. Description: 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
I. Typical Properties 
 Acidity/alkalinity     :             pH = 5.5–8.0 for a 1% w/w aqueous solution. 
 Density (bulk)          :             0.341 g/cm3 
 Density (tapped)      :             0.557 g/cm3 
 Density (true)           :            1.326 g/cm3 
 Melting point           :            Browns at 190–200°C; chars at 225–230°C. 
                                                          Glass transition temperature is 170–180°C. 
 Viscosity (dynamic): a wide range of viscosity types are commercially available. 
Aqueous solutions are most commonly prepared, although hypromellose may also 
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be dissolved in aqueous alcohols such as ethanol and propan-2-ol provided the 
alcohol content is less than 50% w/w.  
Typical viscosity values for 2% (w/v) aqueous solutions of Methocel (Dow 
Chemical Co.). Viscosities measured at 20°C. 
                        Table 2.2: Various grades of hypromellose 
Methocel product               USP 28 designation    Nominal viscosity  
Methocel K100 Premium LVEP 2208 100 
Methocel K4M Premium 2208 4000 
Methocel K15M Premium 2208 15000 
Methocel K100M Premium 2208 100000 
Methocel E4M Premium 2910 4000 
Methocel F50 Premium 2906 50 
Methocel E10M Premium CR 2906 10000 
Methocel E3 Premium LV 2906 3 
Methocel E5 Premium LV 2906 5 
Methocel E6 Premium LV 2906 6 
Methocel E15 Premium LV 2906 15 
Metolose 60SH 2910 50,4000,10000 
Metolose 65SH 2906 50,400,1500,4000 
Metolose 90SH 2208 100,400,4000,15000 
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 Solubility: soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of 
ethanol and dichloromethane, mixtures of methanol and dichloromethane, and 
mixtures of water and alcohol.  
 Moisture content: hypromellose absorbs moisture from the atmosphere; the 
amount of water absorbed depends upon the initial moisture content and the 
temperature and relative humidity of the surrounding air.  
J. Stability and Storage Conditions 
Hypromellose powder is a stable material, although it is hygroscopic after drying. 
Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity of solutions. 
Hypromellose undergoes a reversible sol–gel transformation upon heating and cooling, 
respectively.  
K. Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, 
hypromellose will not complex with metallic salts. 
2.3.2. SODIUM BICARBONATE                                               (Rowe R.C., et al., 2003) 
A. Nonproprietary Names 
BP: Sodium bicarbonate, JP: Sodium bicarbonate, USP: Sodium bicarbonate 
B. Synonyms 
Baking soda; E500; Effer-Soda; monosodium carbonate; Sal de Vichy; sodium 
acid carbonate; sodium hydrogen carbonate. 
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C. Chemical Name and CAS Registry Number:  
Carbonic acid monosodium salt [144-55-8] 
D. Molecular Weight:  84.01 
E. Structural Formula: NaHCO3 
F. Functional Category: Alkalizing agent; therapeutic agent. 
G. Description: 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with a saline, 
slightly alkaline taste. The crystal structure is monoclinic prisms. Grades with different 
particle sizes, from a fine powder to free-flowing uniform granules. 
H. Typical Properties 
 Acidity/alkalinity :   pH = 8.3 for a freshly prepared 0.1 M aqueous solution at    
                                  25° C. 
 Density (bulk)      :   0.869 g/cm3 
 Density (tapped)  :   1.369 g/ cm3 
 Melting point       :   270° C (with decomposition) 
 Moisture content  :   below 80% RH, the moisture content is less than 1% w/w.  
 Solubility: 
Solubility of sodium bicarbonate 
                              Table 2.3: Solubility of sodium bicarbonate 
Solvent Solubility at 20° C unless otherwise stated 
3.4 4.6 
3.2 4.0 
4.1 4.4 
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I. Applications in Pharmaceutical Formulation or Technology 
Sodium bicarbonate is generally used in pharmaceutical formulations as a source 
of carbon dioxide in effervescent tablets and granules. In effervescent tablets and 
granules, sodium bicarbonate is usually formulated with citric and/or tartaric acid; 
combinations of citric and tartaric acid are often preferred in formulations as citric acid 
alone produces a sticky mixture that is difficult to granulate, while if tartaric acid is used 
alone, granules lose firmness. 
J. Uses of sodium bicarbonate 
Use                                               Concentration (%) 
Buffer in tablets                            10–40 
Effervescent tablets                       25–50 
K. Stability and Storage Conditions 
When heated to about 50° C, sodium bicarbonate begins to dissociate into carbon 
dioxide, sodium carbonate, and water; on heating to 250–300°C  
 
2.3.3. MAGNESIUM STEARATE                                             (Rowe R.C., et al., 2003) 
A. Nonproprietary Names: 
BP: Magnesium stearate, JP: Magensium stearate, USP: Magnesium stearate 
B. Synonyms: Metallic stearate, magnesium salt. 
C. Chemical Name:  Octadecanoic acid, magnesium salt 
D. Empirical Formula: C36H70MgO4 
E. Molecular Weight:  591.34 
F. Structural Formula: [CH3 (CH2)16COO]2 Mg 
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G. Functional Category:  Tablet and capsule lubricant. 
H. Description: 
Magnesium stearate is a fine, white, precipitated or milled, impalpable powder of 
low bulk density, having a faint odor of stearic acid and a characteristic taste.  
I. Typical Properties:  
Density (bulk): 0.159 g/cm
3 
Density (tapped): 0.286 g/cm
3 
J. Solubility: 
Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%) 
K. Applications in Pharmaceutical Formulation: 
Magnesium stearate is used in foods, and pharmaceutical formulations. It is 
primarily used as a lubricant in capsule and tablet manufacture at concentrations between 
0.25 – 5.0%.  
L. Stability and Storage Conditions: 
Magnesium stearate is stored in a well-closed container in a cool, dry place. 
 
 2.3.4. LACTOSE
 
A. Synonyms: Anhydrous Lactose NF 60M, lactosum, milk sugar. 
B. Chemical Name: O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranose . 
C. CAS Registry Number: [63-42-3] 
D. Molecular Weight: 342.30. 
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E. Structural Formula:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F. Functional Category:  
Binding agent; directly compressible tableting excipient; lyophilization aid; tablet 
and capsule filler. 
G. Applications in Pharmaceutical Formulation or Technology 
Anhydrous lactose is widely used in direct compression tableting applications and 
as a tablet and capsule filler and binder. Anhydrous lactose can be used with moisture-
sensitive drugs due to its low moisture content. 
H. Angle of repose:  39° for Pharmatose DCL 21 and 38° for Super-Tab Anhydrous. 
I. Density (true): 1.589 g/cm3 for anhydrous β-lactose; 1.567 g/cm3 for Super-Tab               
Density (bulk): 0.68 g/cm3 for Pharmatose DCL 21; 0.67 g/cm3 for Pharmatose 
DCL 22;   0.65  g/cm3 for Super-Tab Anhydrous. 
Density (tapped): 0.88 g/cm3 for Pharmatose DCL 21; 0.79 g/cm3 for Pharmatose  
DCL 22; 0.87 g/cm3 for Super-Tab Anhydrous. 
J.  Melting point:         
 223.0°C for anhydrous α-lactose; 
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 252.2°C for anhydrous β-lactose; 
 232.0°C (typical) for commercial anhydrous lactose. 
K. Moisture content: Anhydrous lactose normally contains upto 0.1% w/w water.  
Lactose monohydrate contains approximately 5% water of crystallization. 
L. Stability and storage:  saturated solutions of β lactose may precipitate crystals of  
lactose on standing. It should be stored in a well closed container in a cool, dry place. 
 
2.3.5. SODIUM LAURYL SULFATE                                       (Rowe R.C., et al., 2003)
 
A. Nonproprietary Names: 
BP: Sodium lauryl sulfate, USPNF: Sodium lauryl sulphate,  PhEur: Natrii lauryl sulfas 
B. Synonyms: Dodecyl sodium sulfate, Elfan240, Sodium mono dodecyl sulfate. 
C. Chemical Name: Sulphuric acid monododecyl ester sodium salt 
D. Empirical Formula: C12H25NaO4S. 
E. Molecular Weight:  288.38. 
G. Functional Category:  Anionic surfactant, detergent, emulsifying agent, tablet 
lubricant. 
H. Description: 
It consists of white or cream to pale yellow colored crystals, flakes or powder 
having smooth feel, a soapy, bitter taste, and a faint odor of fatty substances. 
I. Typical Properties: Density: 1.07 g/cm
3
 
J. Solubility: Practically insoluble in ethanol, chloroform; freely soluble in water. 
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K. Applications in Pharmaceutical Formulation: 
            SLS is used as surfactant lubricant.  
L. Stability and Storage Conditions: 
            It is stable under normal storage conditions. However in solution under extreme 
conditions, i.e; P
H
 2.5 (or) below it may undergoes hydrolysis to lauryl alcohol and 
sodium bisulphate. 
           The bulk material should be a stored in a well closed container away from strong 
oxidizing agents in a cool, dry place. 
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3. AIM AND OBJECTIVES 
Anti microbial agents are orally administered to produce a systemic effect, but 
this application induces some side effects like hypersensitivity, gastrointestinal 
intolerance, development of bacterial resistance. Furthermore, it is reported that this kind 
of administration does not guarantee an adequate concentration at the action site because 
the active product is not retained locally for a sufficient period of time. A solution to 
these problems could be the local administration of the drug formulated in a controlled 
release delivery system was developed for site specific delivery of ofloxacin. 
           Ofloxacin is a synthetic chemotherapeutic antibiotic of fluroquinolones drug class 
considered to be a second generation fluroquinolones. Ofloxacin is the broad-spectrum 
antibiotic that is active against both Gram-positive and Gram-negative. Ofloxacin is more 
potent against gram positive organism and certain anaerobes when compared with other 
fluroquinolone antibiotics. 
Floating sustained release delivery systems for oral dosing are effective in 
achieving optimal therapy with drugs that have a narrow therapeutic range of blood 
concentration which eliminate rapidly. One of the methods of fabricating sustained 
release formulations in incorporation of the drug in the floating matrix containing a 
hydrophilic rate controlling polymer. The FDDS is able to prolong the retention time of a 
dosage form in the stomach, thereby improving the oral bioavailability of the drug. These 
are matrix type of systems prepared with the help of swellable polymer and various 
effervescent agents, e.g. sodium bicarbonate and citric acid.  
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 But, till now not a single attempt has been made to develop a floating tablets of 
ofloxacin which release the drug slowly over an extended period of time with prolonged 
gastric retention. 
 Hence, the present work involves use of gastric floating drug delivery system  for 
ofloxacin which is primarily absorbed in the stomach and upper intestine segments. This 
will ensure minimum fluctuations in the plasma drug concentration and reduced dosing 
frequency which will result into improved patient compliance. 
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                                5. MATERIALS AND EQUIPMENTS 
 
5.1. LIST OF MATERIALS USED WITH SOURCES 
Table 5.1: List of Materials and their Suppliers 
Sl. 
No. 
Name of Material Supplied by 
1 Ofloxacin Goodman pharmaceuticals, Pondicherry. 
2 HPMC K15 Loba chemie,Mumbai. 
3 HPMC K100 Cipla Laboratories, Mumbai. 
4 Sodium bicarbonate Cipla Laboratories, Mumbai. 
5 Sodium lauryl sulfate Cipla Laboratories, Mumbai. 
6 Magnesium stearate Loba Chemicals, Mumbai 
7 Lactose Loba Chemicals, Mumbai 
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5.2. LIST OF USED EQUIPMENTS WITH MAKE/MODEL:  
         Table 5.2: List of equipments with their make and model  
Sl. 
No. 
Name of the equipment Make 
1 Electronic balance Shimadzu, Japan 
2 UV-Visible spectrophotometer Shimadzu, Japan 
3 
16 Stations rotary tablet 
compression machine 
Cadmach, Ahmedabad, India 
4 Hardness tester Monsanto 
5 Roche friability tester Veego scientifics,  Mumbai 
6 FTIR Spectrophotometer Perkin elmer-Pharmaspec-1 
7 Dissolution test apparatus Veego scientifics,  Mumbai 
8 Digital pH meter Elico scientifics,  Mumbai 
9 Hot air oven 
Prescision scientific co., 
Chennai 
10 Vernier calipers Indolabs, Chennai 
11 Humidity chamber Labtech, Ambala 
12 Tap density apparatus Indolabs, Chennai 
13 Melting point test apparatus 
Prescision scientific co., 
Chennai 
14 Standard sieve Jayant scientific, India 
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6. PRE-FORMULATION STUDIES 
 
6.1. CHARACTERIZATION OF DRUG:  
6.1.1. Colour and Appearance:                                (Indian Pharmacopoeia, 2007) 
      The sample was observed visually. 
6.1.2. Melting Point:                                                 (Indian pharmacopeia,2007) 
Melting point of drug was determined by Melting point test apparatus. 
6.1.3. Solubility Study:                                              (Indian Pharmacopoeia, 2007) 
          Solubility study was carried out as per the I.P.2007.In this maximum amount of 
solvent required to dissolve the solute was determined. 
6.1.4. Identification of drug: 
6.1.4.1. Identification of drug by FTIR:  
FTIR study was carried out to identify drug. Infrared spectrum of  Ofloxcain was 
determined on Fourier transform Infrared Spectrophotometer using KBr dispersion 
method. The base line correction was done using dried potassium bromide. Then the 
spectrum of dried mixture of drug and potassium bromide was run followed by using 
Parkin elmer-Pharmaspec-1 FTIR spectrophotometer. The absorption maximums in 
spectrum obtained with the substance being examined correspond in position and relative 
intensity to those in the reference spectrum 
6.1.4 Spectral Analysis of Ofloxacin:                                    (Bhusari KP; 2009) 
6.1.4.1 UV Spectral Analysis of Ofloxacin: 
6.1.4.1.1. UV Spectral Analysis of Ofloxacin in 0.5N acetic acid: 
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6.1.4.1.1.1. Determination of absorption maximum in 0.5N acetic acid: 
Stock solution of Ofloxacin (1000 μg/ml) was prepared by dissolving 50 mg 
of Ofloxacin in 50 ml of 0.5 N Acetic acid. Dilutions of  ( 2-10 μg/ml) were performed. 
The solution was scanned in range of wavelength 210-400 nm, for determining absorption 
maxima (λmax) of Ofloxacin by drug by using Shimadzu-1700 Pharmaspec UV-VISIBLE 
spectrophotometer. 
6.1.4.1.1.2. Preparation of Standard Curve of Ofloxacin: 
          Stock solution of Ofloxacin (1000 μg/ml) was prepared by dissolving 
50ml of drug of 0.5N Acetic acid. The dilutions of 2-10 μg/ml were prepared from stock 
solution. The UV absorbances of these solutions were determined spectrometrically at λmax 
294 nm using UV-VISIBLE Spectrophotometer. 
 Assay of Ofloxacin: 
Accurately weighed 50 mg of Ofloxacin was dissolved in little quantity of 
0.5 N acetic acid and volume was adjusted to 50 ml with the same to prepare standard 
solution having concentration of 1000 μg/ml and the volume was adjusted with 0.5 N acetic 
acid to get a concentration of 100 μg/ml. From this stock solution, 0.5 ml was pipette out 
and transferred to 10 ml volumetric flask and final volume was adjusted with 0.5N acetic 
acid. Absorbance values of these solutions were measured against blank at 294 nm using 
UV-Visible spectrophotometer. The percentage purity of drug was calculated by using 
calibration graph method. 
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6.1.4.1.2.2. . UV Spectral Analysis of Ofloxacin in 0.1 N HCl: 
6.1.4.1.2.2.1. Determination of absorption maximum in 0.1 N HCl: 
Stock solution of Ofloxacin (1000 μg/ml) was prepared by dissolving 50 
mg of Ofloxacin in 50 ml of 0.1 N HCl. Dilutions of ( 3-15 μg/ml) were performed. The 
solution was scanned in range of wavelength 210-400 nm, for determining absorption 
maxima (λmax) of Ofloxacin by drug by using Shimadzu-1700 Pharmaspec UV-VISIBLE 
spectrophotometer. 
6.1.4.1.2.2.2. Preparation of Standard Curve of Ofloxacin: 
Stock solution of Ofloxacin (1000 μg/ml) was prepared by dissolving 
50ml of drug of 0.1 N HCl. The dilutions of 3-15 μg/ml were prepared from stock 
solution. The UV absorbances of these solutions were determined spectrometrically at 
λmax 293.2 nm using UV-VISIBLE Spectrophotometer. 
. 
6.1.5. Loss on drying:                                             (Indian Pharmacopoeia, 2007) 
Loss on drying is the loss of weight expressed as percentage w/w resulting 
from volatile matter of any kind that can be driven off under specified condition. The test 
can be carried out on the well mixed sample of the substance. 
 
      Initial weight of substance – Final weight of substance 
Loss on drying =     
                                           Initial weight of substance 
 
 
 
×100 
Intragastric drug delivery system of Ofloxacin                             Pre-Formulation Studies         
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  65 
 
6.2. DRUG - POLYMERS COMPATABILITY STUDIES : 
  Drug polymers studies holds great importance in designing a formulation 
In drug formulation it is essential to evaluate the possible interactions between the active 
principle and the polymers, as the choice of the polymers should be performed in relation 
to the drug delivery, to their compatibility with the same drug and to the stability of the 
final product. 
6.2.1. Differential Scanning Calorimetry Study (DSC):                     (Jain N. K., 2008) 
 Ofloxacin powder was mixed with various polymers in the ratio of 1:1. 
The mixture of drug with polymers to maximize the like hood of obscuring an 
interaction. Mixture should be examined under Nitrogen to eliminate oxidative and 
pyrolytic effect at a standard heating rate (10
0
C/minute) on DSC. Over a temperature 
range, which will encompass any thermal changes due to the mixture of drug with 
polymers. Thermograms of pure drug are used as a reference.      
 Appearance or disappearance of one or more peaks in thermograms of 
drug with polymer are considered as a indication of interaction. 
6.3 PREPARATION AND EVALUATION OF POWDER BLENDS 
6.3.1 PREPARATION OF POWDER BLENDS: 
  All ingredients were weighed and passed through mesh #40 seperately. 
The drug and polymer were blended first in mortar and pestle then the remaining 
ingredients are added in that and blended for 20 min. Finally the blend is passed through 
mesh # 20 and used for evaluation of flow characteristics.   
6.3.2 EVALUATION OF MICROMERITIC PROPERTIES OF POWDERS 
                                       (Aulton M.E., 2007; Sinko P. J., 2009; Ansel S. C.,) 
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6.3.2.1 Angle of Repose:                                   
  The angle of repose was determined by the funnel method. The accurately 
weighed (10 gms) powder was taken in a funnel. The height of the funnel was adjusted in 
such a way that the tip of the funnel just touched the apex of the heap of powder. The 
powder was allowed to flow through the funnel freely onto a clean surface. The diameter 
of the powder cone was measured and angle of repose was calculated using the following 
equation:       
       tan  = h/r 
Where h is the height of powder cone and r is the radius of the powder cone.  
Relationship between angle of repose ( ) and flowability is shown in the Table 6.1. 
          Table 6.1:  Relationship between Angle of Repose ( ) and Flowability 
Sl. No. Angle of repose( ) Flowability 
1 <20 Excellent 
2 20 – 30 Good 
3 30 – 35 Passable 
4 >40 Very poor 
 
6.3.2.2. Bulk Density and Tapped Bulk Density: 
 
                        An accurately weighed (10 gms) powder from each formula was 
lightly shaken to break any agglomerates formed and it was introduced into a measuring 
cylinder. The volume occupied by the powder was measured which give bulk volume. 
The measuring cylinder was tapped until no further change in volume was noted which 
gave the tapped volume. Both Bulk Density (BD) and Tapped Bulk Density (TBD) of 
powder were determined using the following formulae. 
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BD = Weight of the powder/Volume of the powder 
TBD = Weight of the powder/Tapped volume of the powder 
6.3.2.3. Carr‟s Compressibility Index:  
   The compressibility index of the powder was determined using following 
Carr’s compressibility index formula. 
                  Carr‟s Compressibility Index (%) = [(TBD-LBD)/ TBD] x100 
Relationship   between % compressibility and flowability is shown in the Table 6.2 
              Table 6.2:  Relationship between % Compressibility and Flowability 
Sl. No. % Comressibility Flowability 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair Passable 
4 23-35 Poor 
5 33-38 Very poor 
6 >40 Very very poor 
 
6.3.2.4. Hausner‟s ratio: 
 Hausner’s ratio is the ratio between tapped density and bulk density. 
 Hausner’s ratio less than 1.25 indicates good flow properties while 
 Hausner’s ratio greater than 1.25 shows poor flow of powder. 
Table 6.3:  Relationship between Hausner‟s ratio and Flowability 
Sl. No. Hausner‟s ratio Flow Property 
1 0.0 - 1.25 Free flow 
2 1.25 - 1.6 Cohesive flow 
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7. FORMULATION OF FLOATING TABLETS  
                                                                    (Vital F. Patel et al, 2006) 
The formulation of Ofloxacin tablets was calculated by using 3
2
 full factorial 
design was used in development of dosage form. In this design, 2 factors were evaluated 
each at three levels and experimental trials were performed using all possible nine 
combinations. In this present investigation, the ratio of HPMC K15:HPMC K100 (X1) 
and content of sodium laurel sulfate (X2) were selected as independent variables. 
The experimental design with corresponding formulations is outlined in table   . 
Content of polymer blend was 15% of the total tablet weight. Blends of HPMC K15 and 
HPMC K100 were evaluated at 85:15, 75:25 and 65:35, while content of SLS was 
evaluated at 0%, 1%, 2% of the total tablet weight. 
            A statistical model incorporating interactive and polynomial terms was used to 
evaluate the response. 
               Y=b0 + b1X1 + b2X2 + b12X1X2 + b11X1X1 + b22X2X2. 
                  Where Y= Dependent variable 
                                b0= arithmetic mean response of 9 runs, 
                                  b1= estimated coefficient factor, Xi 
The main effect (X1:X2) represents the average result of changing one factor at a 
time from its low to high value. The interaction term (X1X2,X2X2) are included to 
investigate non linearity. 
Independent variables and their selected levels for floating tablet formulation 
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                            Table 7.1: Ratio’s of polymer used in the formulation 
Sl.No Code values Actual values in mg 
HPMC K15:HPMC K100 SLS 
1 -1 85:15 0% 
2 0 75:25 1% 
3 1 65:35 2% 
 
7.1 FORMULATION OF OFLOXACIN TABLET USING 32 FULL FACTORIAL 
DESIGNS 
                 Table 7.2: Formulation of ofloxacin using 3
2
 full factorial design 
Sl.NO BATCH 
CODE 
Variable level in Code 
X1 X2 
1 F1 +1 +1 
2 F2 +1 0 
3 F3 +1 -1 
4 F4 0 +1 
5 F5 0 0 
6 F6 0 -1 
7 F7 -1 +1 
8 F8 -1 0 
9 F9 -1 -1 
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Table 7.3: Composition of floating Tablets of Ofloxacin: 
Sl. 
No. 
Ingredients 
(mg/tablet) 
Formulations Code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Ofloxacin 400 400 400 400 400 400 400 400 400 
2 
HPMCK15 
HPMCK100 
58.5 
31.5 
58.5 
31.5 
58.5 
31.5 
67.5 
22.5 
67.5 
22.5 
67.5 
22.5 
76.5 
13.5 
76.5 
13.5 
76.5 
13.5 
3 
Sodium 
lauryl sulfate 
12 6 0 12 6 0 12 6 0 
4 
Sodium 
bicarbonate 
(10%) 
60 60 60 60 60 60 60 60 60 
5 
Magnesium 
stearate(1%) 
6 6 6 6 6 6 6 6 6 
6 Lactose 32 38 44 32 38 44 32 38 44 
7 Total 600 600 600 600 600 600 600 600 600 
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7.2 COMPRESSION OF POWDER BLENDS INTO TABLETS      
                                                                                                      (Dhirendra K., et al., 2010)                                                                                
           After evaluation of powder blend, the floating tablets were prepared by direct 
compression method using (9 mm diameter, round flat faced punches) multiple punch 
tablet compression machine (Cadmach Machinery Ltd., Ahmedabad, India). Each tablet 
contained 400 mg of Ofloxacin; the batch size for each formulation was 100 tablets. 
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8. EVALUATION OF TABLETS 
 
 Evaluation of Tablets: 
 Physicochemical Properties of Tablets 
 Appearance 
 Thickness 
 Hardness 
 Friability 
 Weight variation 
 Drug content 
 Swelling Index of Tablets 
 In vitro Buoyancy Studies 
 In vitro Drug Release 
 Kinetics of in vitro Drug Release 
 Stability Studies 
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8.1. Physicochemical Properties of Tablets: 
8.1.1. Appearance:                                                   (Lachman L., 1990) 
           The tablets were visually observed for any capping, chipping and lamination. 
8.1.2. Size and Thickness:  
          The size and thickness of tablet can vary with no change in weight due to 
difference in Density of granulation, the pressure applied to the tablets and speed of the 
tablet compression machine. The thickness of the tablets was determined using a Vernier 
caliper. Three tablets from each type of formulation were used and average values were 
calculated. 
8.1.3. Hardness:  
          There is a certain requirement of hardness in tablets so as to withstand the 
mechanical shocks during handling, manufacturing, packaging and shipping. Hardness 
tester (Monsanto tester) was used to measure hardness of tablets. The tablet was held 
along its oblong axis in between the two jaws of the tester. At this point, reading should 
be taken as a zero kg/cm
2
. Then constant force was applied by rotating the knob until the 
tablet fractured. The value at this point was noted in kg/cm
2
.  
8.1.4. Friability:  
          Friability is the measure of tablet strength. This test subjects a number of tablets to 
the combined effect of shock abrasion by utilizing a plastic chamber which revolves at a 
speed of 25 rpm for four minutes, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of pre-weighed tablets was placed in Roche friabilator which was 
then operated for 100 revolutions. The tablets were then dedusted and reweighed. Percent 
friability (% F) was calculated as follows,    
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% Friability = (Initial weight - Final weight / Initial weight) x 100. 
 
8.1.5. Weight Variation:                                              (Indian Pharmacopoeia, 2007) 
 The weight variation test is done by taking 20 tablets randomly and they were 
weighed individually. The composite weight divided by 20, provides an average weight 
of tablet. Not more than two of the individual weight deviates from the average weight by 
% deviation allowed and none should deviate by more than twice it’s percentage.  
Table 8.1: Specifications of % Weight Variation Allowed in Tablets as per Indian 
Pharmacopoeia 
Average Weight of Tablet %  Deviation allowed 
80 mg or less 10 
More than 80 mg but less that 250 mg 7.5 
250  mg  or more 5 
 
8.1.6. Drug Content :                                                    (Hanna Hopkala, 2000) 
  Twenty tablets were weighed and finely powdered. An accurately weighed 
quantity of powder equivalent to 50 mg of Ofloxacin was taken in 50 ml volumetric 
flask  and dissolved in 25 ml of 0.5 N Acetic acid; it was further diluted up to the mark 
with same solvent. The solutions were then filtered and filterate gets diluted to get 5 
μg/ml concentration of Ofloxacin. The solution was then read at 294 nm by using UV-
VISIBLE spectrophotometer. 
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8.2.  Swelling Index of Tablets:                                          (NG Raghavendra Rao,2011) 
          The extent of swelling was measured in terms of percentage weight gain by the 
tablet. The swelling behaviour of formulation F1-F9 was studied. One tablet from each 
formulation was kept in a petritdish containing 0.1N HCl. The tablet was withdrawn in 
time intervals, soaked with tissue paper, and weighed. Weights of the tablet were noted 
and the process was continued till the end 12 hrs. Percentage weight gain by the tablet 
was calculated by formula.   
 
                                          Weight of swollen tablet - Initial weight of tablet 
      Swelling Index    =                                                                                        
                                                               Initial weight of tablet 
 
8.3. In vitro Buoyancy Studies:                               (NG Raghavendra Rao et al,2011) 
  The time taken for tablet to emerge on the surface of the medium is called the 
floating lag time or buoyancy lag time and duration of time the dosage form constantly 
remains on the surface of the medium is called total floating time. The  buoyancy of the 
tablets was performed by using 0.1 N HCl. The time of duration of floatation was 
observed visually. 
8.4. In vitro Drug release studies of Tablets:     (Indian Pharmacopoeia,2007) 
          The release rate of Ofloxacin from floating tablets was determined using USP 
Dissolution Testing Apparatus type-II (paddle method; Veego Scientific VDA-8DR, 
Mumbai, India). The dissolution test was performed using 900 ml of 0.1N HCl, at 37 ± 
0.5°C and 50 rpm. A sample (5 ml) of the solution was withdrawn from the dissolution 
apparatus hourly and the samples were replaced with fresh dissolution medium. The 
samples were filtered through a 0.45 μ membrane filter and diluted to a suitable 
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concentration with 0.1N HCl. Absorbance of these solutions was measured at 293.2 nm 
using a Shimadzu-1700 Pharmaspec UV-VISIBLE spectrophotometer. For each 
formulation, the experiments were carried out in triplicate. The release data were 
calculated by using PCP disso V3 software. 
8.5. Kinetics of In vitro Drug Release:                                  (Brahmankar D.M., 2009) 
         To analyze the mechanism of drug release from the tablets the In-vitro drug release, 
data were fitted to kinetic models such as zero order, first order, Higuchi and Korsmeyer- 
Peppas. 
 Zero order:  
K0 - zero-order rate constant expressed in units of concentration/time, t - time in hrs. 
 First order:  
Where   C0 - is the initial concentration of drug, K - first order constant, t - time in 
hrs.  
 Higuchi :  
Where   Qt - amount of the release drug in time t, K- kinetic constant, t- time in hrs. 
 Korsmeyer Peppas:     
Where   Mt - represents amount of the released drug at time t,  
             M∞- is the overall amount of the drug (whole dose) released after 12 hrs  
               K- is the diffusional characteristic of drug/ polymer system constant  
                n- is a diffusional exponent that characterizes the mechanism of release of drug.  
8.6. STABILITY STUDIES:                                  (Anand Patel,2009) 
              To assess the drug and formulation stability, stability studies were done 
according to International Conference on Harmonization and World Health Organisation 
guidelines. The tablets were stored at 40ºC/75% relative humidity in closed high-density 
C = K0t                                                                                                               
LogC = LogC0 – Kt / 2.303                                                                             
Mt / M∞ = Kt n                                                                                                                                                                                                    
Qt = Kt
1/2
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polyethylene bottles for 3 months. Tablets were analyzed at specific time intervals for 
hardness, drug content, invitro buoyancy studies, invitro drug release studies. 
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9. RESULTS AND DISCUSSION 
  
 CHARACTERIZATION OF DRUG: 
9.1.1. Colour and Appearance: 
The drug (Ofloxacin) colour is “Off-white to pale yellow” as same as the reported 
reference. 
9.1.2. Melting Point: 
The Melting point of Ofloxacin was found to be 256.056 ± 0.040.  The reported 
melting point of Ofloxacin is 250-257
0
C. Hence, observed values are complies with 
USP.  
9.1.3. Solubility Study: 
The Solubility of Ofloxacin in different solvents is given below: 
Table 9.1: Solubility of Ofloxacin in Different Solvents 
 
Sl. No. 
 
Solvent 
Parts of solvent 
required per part of 
solute 
 
Inference 
1 Acetic acid 10  Soluble. 
2 Water 460 Slightly soluble. 
3 0.1 N HCl 28  Soluble. 
 
9.1.4. IDENTIFICATION OF DRUG: 
               Identification of drug was performed by FTIR spectroscopic method 
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9.1.4.1. Fourier Transform Infra-Red Spectroscopy (FTIR): 
The IR spectrum of Ofloxacin is shown in figure 9.1. The Interpretation of IR 
frequencies are show in Table 9.2. 
Fig 9.1: FTIR of ofloxacin 
 
Interpretation of FTIR Spectrum: 
Table 9.2 shows the peaks observed at different wave numbers and the functional 
group associated with these peaks.
 
The major peaks are identical to functional group of 
Ofloxacin. Hence, the sample was confirmed as Ofloxacin.  
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Table 9.2: Characteristic Frequencies in FTIR Spectrum of Ofloxacin 
Functional groups Wave No. (cm
-1)
 
C-H out of plane bending 799 
C-O-C stretching ether group 1050 
C-F stretching 1130 
C-O stretching COOH 1291 
C-C stretching 1459 
C=O aromatic stretching 1531 
C=O stretching ketones 1620 
 
9.1.5. SPECTROSCOPIC STUDIES: 
9.1.5.1. UV Spectroscopy: 
9.1.5.1.1. Determination of λmax and Preparation of Calibration Curve of            
               Ofloxacin by using 0.5 N Acetic acid: 
  UV absorption spectrum of Ofloxacin in 0.5 N Acetic acid shows λmax at 
294nm. Absorbance obtained for various concentrations of Ofloxacin in 0.5 N Acetic 
acid are given in Table 9.3. The graph of absorbance  concentration for Ofloxacin was 
found to be linear in the concentration range of 2-10 μg /ml. The drug obeys Beer- 
Lambert’s law in the range of 2-10 μg /ml. 
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              Fig. 9.2: Absorption maximum of Ofloxacin in 0.5N Acetic acid 
Table 9.3: Concentration and Absorbance data for Calibration Curve of Ofloxacin in    
0.5 N Acetic acid 
Sl. No. Concentrations(μg/ml) Absorbance at 294nm. 
1 2 0.191 
2 4 0.360 
3 6 0.540 
4 8 0.711 
5 10 0.870 
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Fig.9.3 Calibration curve of Ofloxacin in 0.5 N acetic acid 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 9.4. 
Table 9.4:  Data for Calibration Curve parameters of Ofloxacin in 0.5 N Acetic acid 
Sl. No. Parameters Values 
1 Slope 0.0850 
2 Intercept 0.0210 
3 Correlation coefficient (R) 0.9998 
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9.1.5.1.2. Assay of Ofloxacin: 
                                        Table 9.5: Assay of Ofloxacin 
Sl. No                   Percentage Purity    Average Percentage purity(%) 
    1                         99.86                
               100.38±0.714     2                        100.10 
    3                        101.20 
 
 The official percentage purity of Ofloxacin is not less than 98.5% and not more than 
101.5%. So it can be declared as pure drug. The percentage purity of raw material 
Ofloxacin was found to be 100.38±0.714. Hence, the sample was concluded as pure 
9.1.5.1.3. Determination of λmax and Preparation of Calibration Curve of Ofloxacin 
by using 0.1N HCl: 
 UV absorption spectrum of Ofloxacin in 0.1N HCl shows λmax at 293.2 nm. 
Absorbance obtained for various concentrations of Ofloxacin in 0.1N HCl are given in 
Table 9.6. The graph of absorbance versus concentration for Ofloxacin was found to be 
linear in the concentration range of 3-15 μg /ml. The drug obeys Beer- Lambert’s law in 
the range of 3-15 μg /ml. 
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                          Fig. 9.4: Absorption maxima of Ofloxacin in 0.1N HCl 
Table 9.6: Concentration and Absorbance data for Calibration Curve of Ofloxacin in 
0.1N HCl: 
Sl. No. Concentrations (μg/ml) Absorbance at 293.2nm 
1 3 0.182 
2 6 0.355 
3 9 0.529 
4 12 0.701 
5 15 0.875 
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                    Fig. 9.5: Calibration curve of Ofloxacin in 0.1N HCl 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 9.7. 
 Table 9.7:  Data for Calibration Curve parameters of Ofloxacin in 0.1N HCl 
Sl. No. Parameters Values 
1 Slope 0.0570 
2 Intercept 0.0089 
3 Correlation coefficient (R) 0.9999 
 
9.1.6. Loss on drying: 
The percentage loss on drying after 5 hours was found to be 0.0797%. The sample 
passes test for loss on drying as per the limits specified in USP. (NMT 0.2%). 
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9.1.DRUG - POLYMERS COMPATIBILITY STUDIES: 
9.2.2. Differential Scanning Calorimetry (DSC):       
A 
 
             
                                      Fig 9.6: DSC  Thermogram of Ofloxacin 
 
                                   
 
                           Fig 9.7:   DSC Thermogram of  Ofloxacin+HPMC K15 
B. 
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Fig 9.8: DSC Thermogram of Ofloxacin+ HPMC K 100 
       
 The results of DSC studies are given in above figures 9.6, 9.7, 9.8. Pure Ofloxacin 
showed sharp endotherm at 256.10°C corresponding to its melting point. There was no 
appreciable change in the melting endotherms of Ofloxacin with HPMCK15, Ofloxacin 
with HPMCK100, as compared to the thermogram of Ofloxacin. So, it could be 
concluded that there is no interaction between Ofloxacin and Polymers used in the 
formulations.  
 
 
 
 
 
C. 
Intragastric drug delivery system of Ofloxacin                                Results and Discussion             
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  88 
 
9.2. EVALUATION OF MICROMERITIC PROPERTIES OF POWDER BLENDS: 
Table 9.8: Micromeritic Properties of Prepared Powder blends 
Formulations 
Code 
Angle of 
Repose  
(
o
) 
LBD 
(gm/ml) 
TBD 
(gm/ml) 
Carr‟s 
Index 
(%) 
Hausner‟s 
ratio 
F1 
24.268± 
0.405 
0.468± 
0.012 
0.520±0.001  
9.803± 
0.015 
1.107± 
0.001 
F2 
25.120± 
0.440 
0.484± 
0.026 
0.541±0.003 
10.360± 
0.020 
1.114± 
0.001 
F3 
25.336± 
0.941 
0.492± 
0.014 
0.540±0.002 
8.826± 
0.040 
1.096± 
0.001 
F4 
24.182± 
0.336 
0.476± 
0.023  
0.571±0.001 
16.440.± 
0.040 
1.196± 
0.001 
F5 
24.883± 
0.886 
0.476± 
0.023 
0.542±0.002 
12.003± 
0.015 
1.117± 
0.001 
F6 
25.386± 
0.820 
0.484± 
0.014  
0.600±0.002 
19.306± 
0.005 
1.256± 
0.001 
F7 
25.623± 
0.812 
0.469± 
0.026 
0.599±0.001 
21.593± 
0.050 
1.254± 
0.001 
F8 
23.875± 
0.353 
0.484± 
0.026 
0.599±0.001 
19.053± 
0.050 
1.234± 
0.001 
F9 
25.153± 
0.881 
0.461± 
0.012 
0.599±0.001 
20.900± 
0.020 
1.236± 
0.001 
             
All the values are expressed as a mean  SD., n = 3 
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9.2.1. Angle of repose: 
            The results for angle of repose are recorded in Table 9.8. Angle of repose ranged 
from 23.875 ± 0.353 to 25.386 ± 0.820. The flow properties of powder blends in all 
formulations exhibit good flow. 
9.2.2.  Bulk density and Tapped bulk density:  
 The results are shown in Table 9.8. The values of BD and TBD were found to be in 
the range from 0.600 ±0.002 to 0.520 ± 0.001 gm/ml and 0.461±0.012 to 0.492± 0.014 
gm/ml respectively. So, it shows that all formulations having good flow properties and 
packability.  
9.2.3.  Carr‟s Compressibility Index:  
 The results for Carr’s Compressibility Index are recorded in Table 9.8.The Carr’s 
Compressibility Index were in the ranged from 9.803 ± 0.015  to 20.900 ± 0.020 %. This 
indicates good flow properties of powder. 
9.2.4. Hausner‟s ratio:  
The result were summarized in Table 9.8.The Hausner’s ratio were found in the 
ranged from 1.107 ± 0.001 to 1.256 ± 0.001. So it indicates good flow properties. 
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9.3.EVALUATION OF TABLETS: 
9.4.1. Evaluation of Physicochemical properties of tablets  
Table 9.9: PhysicoChemical Properties of Tablets 
Formulations 
Code 
Thickness* 
(mm) 
 
Weight 
Variation*** 
(%) 
 
Hardness** 
(kg/cm
2
) 
 
Friability* 
(%) 
 
Drug 
Content* 
(%) 
F1 8.97±0.048 0.191±0.135 3.50±0.097 0.308±0.096 99.20±0.040 
F2 8.94±0.052 0.136±0.091 3.49±0.120 1.090±0.030  97.20±0.040 
F3 8.50±0.527 0.169±0.166 3.66±0.084 0.341±0.074 95.17±0.080 
F4 8.85±0.306 0.190±0.084 3.75±0.053 0.529±0.025 90.36±0.120 
F5 8.77±0.0408 0.167±0.133 3.56±0.097 0.891±0.023 88.25±0.040 
F6 8.87±0.309 0.145±0.073 3.15±0.242 0.893±0.008 87.32±0.090 
F7 8.94±0.070 0.158±0.117 4.48±0.676  0.330±0.052 86.32±0.050 
F8 8.98±0.042 0.147±0.90 3.27±0.437 0.300±0.008 83.95±0.078 
F9 8.97±0.048 0.146±0.077 3.56±0.097 0.570±0.940 82.29±0.150 
 
*All the values are expressed as a mean  SD., n = 3 
** All the values are expressed as a mean ± SD., n=9 
***All the values are expressed as a mean ± SD., n=20 
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9.3.1.1.Appearance:  
The tablets were observed visually and did not show any defects such as capping, 
chipping and lamination after punching.    
9.3.1.2.Thickness:  
The thickness of formulations ranged from 8.85 ± 0.306 mm to 8.98 ± 0.042 . The 
values are recorded in Table 9.9. 
9.3.1.3.Weight Variation:  
The percentage deviation from average tablet weight for all the formulations 
ranged from 0.136±0.091 to 0.190±0.135 %. The results are within the specified limits 
and showed in Table 9.9. Hence all formulations complied with the test for weight 
variation as per IP. 
9.3.1.4.Hardness:  
The results of Hardness of tablets were recorded in Table 9.9. It was found that 
the values are ranged from 3.15 ± 0.097 to 4.48 ± 0.676 kg/cm
2
. Hardness values were 
satisfactory and indicated good mechanical strength of tablets. 
9.3.1.5. Friability:  
The Percentage Friability of all the formulations showed in Table 9.9. The results 
are ranged from 0.390±0.030  to 0.893±0.008%. So, the percentage loss of Friability of 
all the formulations was found to be less than 1 %. 
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9.3.1.6.  Drug content:  
Drug content was found to be uniform among different batches of tablets and 
ranged from 82.29 ± 0.15 to 99.20 ± 0.04%. These results showed that the all 
formulations having percentage drug content within the specified limits as per USP. 
9.3.2. IN VITRO BUOYANCY STUDIES: 
9.3.2.1. Floating lag time: 
                   Table 9.10: In vitro buoyancy studies 
Formulation code Floating lag time (s) Total floating time (h) 
F1 36.5±0.25 >12 
F2 34.6±0.35 >12 
F3 32.5±0.30 >12 
F4 30.8±0.31 >12 
F5 29.4±0.25 >12 
F6 28.2±0.30 >12 
F7 26.2±0.35 >12 
F8 25.4±0.35 >12 
F9 24.6±0.25 >12 
 
 
Fig 9.9: Comparision of Floating lag time studies for different formulations (F1-F9) 
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Fig 9.10: Floating lag time at initial stage 
 
Fig 9.11: Tablet start to rise up to the 
surface 
                  
 
      
Fig 9.12: Floating lag time at 36.50 sec Fig 9.13: Floating lag time after 12 hrs 
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The investigated gastric floating system employed sodium carbonate as a gas 
generating agent dispersed in hydro gel matrix (HPMCK15,HPMCK100). The in-vitro 
test revealed the ability of most formulation to maintain buoyant more than 12 hrs and 
shown in fig 9.9.This suggests that the gel layers, formed by the investigated polymers 
enabled efficient entrapment of generated gas bubbles. The possible increase in tablet 
porosity made it float on the test medium (0.1N HCl) for this extended period of time. 
           These matrices are fabricated so that upon on arrival in the stomach. 
Carbondioxide gas is liberated by the acidity of gastric contents and is entrapped in a 
gellified hydro colloid. A decrease in specific gravity passes the dosage form to float on 
the surface of the medium. The extended residence time of drug in stomach could cause 
increased absorption due to the fact that deuodenum was the main absorption site for 
Ofloxacin. One of the factor influencing behaviour of effervescent system is their floating 
lag time. As shown in the table 9.10 the, HPMC and SLS ratio has a marked effect on 
floating lag time of all the formulations prepared with a constant sodium bicarbonate 
ratio (10%w/w). 
           The floating lag time of formulation F1, F2 and F3 was found to be 36.5, 34.6, 
32.5 respectively. 30.8, 29.4 and 28.2 for F4, F5 and F6. 26.2, 25.4 and 24.6 for F7,F8 
and F9 respectively. 
            This above phenomena might be due to the generation of large amounts of 
effervescence with 10% sodium bicarbonate. This would lead to an increasing rate of 
pore formation and consequently rapid hydration of tablets. 
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9.3.3. SWELLING INDEX STUDY: 
 Swelling Index data of formulation F1, F2, F3: 
Table 9.11: Swelling Index data of formulation F1, F2, F3  
Sl. No. 
Time 
(hours) 
Swelling Index 
F1 F2 F3 
1 0 0.000 0.000 0.000 
2 1 1.74±0.152 1.59±0.035 1.25±0.031 
3 2 1.91±0.0301 1.91±0.030 1.53±0.042 
4 3 2.04±0.151 2.19±0.053 1.69±0.030 
5 4 2.21±0.030 2.40±0.041 1.91±0.022 
6 5 2.59±0.112 2.53±0.032 2.13±0.030 
7 6 3.02±0.054 2.92±0.030 2.63±0.041 
8 7 3.10±0.042 2.99±0.073 2.91±0.072 
9 8 3.35±0.030 3.21±0.022 2.64±0.032 
10 9 3.23±0.070 3.03±0.040 2.49±0.030 
11 10 2.97±0.091 2.87±0.030 2.27±0.031 
12 11 2.81±0.031 2.71±0.052 2.08±0.053 
13 12 2.79±0.040 2.70±0.031 2.07±0.030 
                  All the values are expressed as a mean  SD., n = 3   
 
                               Fig 9.14: Swelling index of formulations F1, F2, F3 
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Swelling Index data of formulation F4, F5, F6: 
Table 9.12: Swelling Index data of formulation F4, F5, F6 
Sl. No. Time (hours) 
Swelling Index 
F4 F5 F6 
1 0 0.000 0.000 0.000 
2 1 1.12±0.030 0.97±0.043 0.76±0.033 
3 2 1.49±0.042 1.21±0.031 0.92±0.030 
4 3 1.76±0.040 1.34±0.072 1.02±0.040 
5 4 1.89±0.030 1.63±0.025 1.26±0.076 
6 5 2.02±0.033 1.70±0.030 1.42±0.129 
7 6 2.17±0.030 1.95±0.021 1.66±0.030 
8 7 2.45±0.029 2.18±0.150 2.04±0.040 
9 8 2.93±0.040 2.74±0.030 1.95±0.051 
10 9 2.82±0.031 2.58±0.054 1.83±0.050 
11 10 2.69±0.030 2.27±0.031 1.62±0.030 
12 11 2.46±0.034 2.03±0.044 1.54±0.021 
13 12 2.45±0.032 2.01±0.041 1.53±0.040 
                         All the values are expressed as a mean  SD., n = 3 
 
                  Fig 9.15: Swelling Index data of formulation F4, F5, F6 
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Table 9.13: Swelling Index data of formulation F7, F8, F9 
Sl. No. Time (hours) 
Swelling Index 
F7 F8 F9 
1 0 0.000 0.000 0.000 
2 1 0.75±0.302 0.71±0.022 0.69±0.022 
3 2 0.95±0.040 0.92±0.020 0.89±0.032 
4 3 1.04±0.030 1.01±0.031 0.99±0.043 
5 4 1.46±0.055 1.36±0.050 1.32±0.012 
6 5 1.62±0.012 1.52±0.030 1.49±0.050 
7 6 2.04±0.020 1.99±0.0312 1.96±0.032 
8 7 2.96±0.090 2.76±0.0570 2.61±0.030 
9 8 1.81±0.054 1.79±0.021 1.72±0.041 
10 9 1.69±0.061 1.66±0.033 1.64±0.070 
11 10 1.57±0.030 1.58±0.030 1.52±0.021 
12 11 1.52±0.040 1.44±0.70 1.40±0.026 
13 12 1.48±0.022 1.42±0.061 1.37±0.030 
All the values are expressed as a mean  SD., n = 3 
 
                              Fig 9.16: Swelling index of formulations F7, F8, F9 
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Fig. 9.17: Comparison of swelling Index of formulations F1-F9 
The floating and drug release profile are dependent upon swelling behaviour of 
the tablets. Swelling index increased as the weight gained by the tablet increased 
proportionally with the rate of hydration. 
Swelling is also a vital factor to ensure buoyancy and drug dissolution of matrix 
tablet. The floating tablet containing HPMCK15 and HPMCK100.  
The comparative swelling Index data of all the formulations were showed in 
Figure 29. From this Figure, it can be observed that the swelling Index of different 
formulations decreased in the following order;  
F1> F2 > F3 > F4 > F5 > F6 > F7 > F8>F9 
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9.3.4. IN VITRO DRUG RELEASE STUDIES: 
9.4.3.1. IN VITRO DRUG RELEASE PROFILE OF TABLETS: 
 Drug release profile for Formulation F1: 
Table 9.14: In vitro drug release data of Formulation F1 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N HCl 
0 0.00 0 0.00 0.00 
2 1 029.51 07.38 0.040 0.00 0.50 
3 2 062.81 15.72 0.010 0.01 1.03 
4 3 096.23 24.06 0.041 0.02 1.53 
5 4 129.59 32.40 0.090 0.02 2.04 
6 5 162.95 40.74 0.030 0.03 2.54 
7 6 196.32 49.08 0.033 0.03 3.04 
8 7 229.68 57.42 0.060 0.04 3.55 
9 8 263.04 65.76 0.030 0.04 4.05 
10 9 296.40 74.11 0.010 0.05 4.55 
11 10 329.77 82.42 0.080 0.05 5.05 
12 11 363.10 90.78 0.021 0.06 5.56 
13 12 393.49 99.12 0.020 0.06 6.06 
     
                               All the values are expressed as a mean  SD., n = 3 
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                        Fig 9.18 : Percentage drug release profile of formulation F1 
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 Drug release profile for Formulation F2: 
Table 9.15: In vitro drug release profile data of Formulation F2 
Sl. 
No. 
Medium 
Time 
(hours) 
Amount of 
drug released 
(mg) 
% Drug Release %DE 
MDT 
(hrs) 
1 
0.1N 
HCl 
0 0.00 0 0.00 0.00 
2 1 28.64 07.16 0.030 0.01 0.50 
3 2 61.14 15.28 0.011 0.01 1.03 
4 3 93.63 23.41 0.032 0.02 1.54 
5 4 126.13 31.53 0.043 0.02 2.04 
6 5 158.62 39.66 0.051 0.03 2.54 
7 6 191.12 47.78 .0410 0.03 3.05 
8 7 223.61 55.90 0.030 0.04 3.55 
9 8 256.11 64.03 0.050 0.04 4.05 
10 9 288.60 72.15 0.021 0.05 4.55 
11 10 321.10 80.28 0.043 0.05 5.05 
12 11 353.60 88.40 0.080 0.06 5.56 
13 12 386.09 96.52 0.030 0.06 6.06 
All the values are expressed as a mean  SD., n = 3 
 
                       Fig 9.19: percentage drug release profile of formulation F2 
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 Drug release profile for Formulation F3: 
Table 9.16: In vitro drug release data of Formulation F3 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N 
HCl 
0 0.00 0 0.00 0.00 
2 1 28.10 07.02 0.031 0.01 0.50 
3 2 60.05 15.01±0.041 0.01 1.03 
4 3 92.01 23.00±0.041 0.01 1.54 
5 4 123.96 30.99±0.012 0.02 2.03 
6 5 155.91 38.98±0.030 0.02 2.54 
7 6 187.87 46.97±0.010 0.03 3.04 
8 7 219.82 54.96±0.060 0.03 3.54 
9 8 251.78 62.94±0.042 0.04 4.06 
10 9 283.73 70.93±0.053 0.04 4.53 
11 10 315.68 78.92±0.041 0.05 5.03 
12 11 347.64 86.91±0.032 0.05 5.58 
13 12 379.59 94.90±0.029 0.06 6.08 
 
All the values are expressed as a mean  SD., n = 3 
 
 
     Fig. 9.20:  Percentage drug release profile of formulation F3 
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Fig 9.21: Comparision of percentage drug release of formulation F1, F2, F3 
 Drug Release Profile for Formulation F4: 
Table 9.17: In vitro drug release data of Formulation F4 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N HCl 
0 0.00 0 0.00 0.00 
2 1 0.086 08.35 0.020 0.01 0.50 
3 2 0.172 17.67±0.010 0.01 1.02 
4 3 0.258 26.98±0.050 0.02 1.53 
5 4 0.344 36.30±0.040 0.02 2.03 
6 5 0.430 45.61±0.030 0.03 2.54 
7 6 0.516 54.93±0.041 0.04 3.03 
8 7 0.602 64.24±0.030 0.04 3.54 
9 8 0.688 73.56±0.041 0.05 4.04 
10 9 0.774 82.81±0.031 0.05 4.54 
11 10 0.860 92.19±0.012 0.06 5.05 
12 11 - - - - 
13 12 - - - - 
All the values are expressed as a mean  SD., n = 3 
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                Fig. 9.22:  Percentage drug release profile of formulation F4 
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 Drug Release Profile for Formulation F5: 
Table 9.18: In vitro drug release data of Formulation F5 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N 
HCl 
0 0.00 0 0.00 0.00 
2 1 32.54 08.13 0.030 0.01 0.50 
3 2 68.93 17.23±0.031 0.01 1.02 
4 3 105.33 26.33±0.061 0.02 1.53 
5 4 141.72 35.45±0.040 0.02 2.04 
6 5 178.12 44.55±0.072 0.03 2.54 
7 6 214.51 53.63±0.051 0.03 3.03 
8 7 250.91 62.73±0.030 0.04 3.52 
9 8 287.31 71.83±0.050 0.05 4.00 
10 9 323.70 80.93±0.041 0.05 4.54 
11 10 360.10 90.02±0.020 0.06 5.04 
12 11 - - - - 
13 12 - - - - 
All the values are expressed as a mean  SD., n = 3 
   
                            Fig 9.23: Percentage drug release profile of formulation F5 
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 Drug Release Profile for Formulation F6: 
Table 9.19: In vitro drug release data of Formulation F6 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N HCl 
0 0.00 0 0.00 0.00 
2 1 32.43 08.11 0.905 0.01 0.50 
3 2 68.76 17.19±0.110 0.01 1.02 
4 3 105.07 26.27±0.036 0.02 1.53 
5 4 141.38 35.34±0.026 0.02 2.04 
6 5 177.69 44.42±0.032 0.03 2.53 
7 6 213.99 53.50±0.041 0.03 3.00 
8 7 250.30 62.58±0.040 0.04 3.58 
9 8 286.61 71.65±0.031 0.04 4.10 
10 9 322.92 80.73±0.051 0.05 4.67 
11 10 359.23 89.81±0.11 0.06 5.02 
12 11 - - - - 
13 12 - - - - 
All the values are expressed as a mean  SD., n = 3 
   
Fig. 9.24.  Percentage drug release profile of formulation F6 
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12
P
e
rc
e
n
ta
ge
 d
ru
g 
re
le
as
e
Time (Hours)
F6
Intragastric drug delivery system of Ofloxacin                                Results and Discussion             
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  107 
 
 
Fig 9.25: comparison of percentage drug release profile of formulation F4 ,F5, F6 
 Drug Release Profile for Formulation F7: 
Table 9.20: In vitro drug release data of Formulation F7 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N 
HCl 
0 0.00 0 0.00 0.00 
2 1 40.55 10.14 0.050 0.01 0.50 
3 2 84.97 21.24±0.031 0.01 1.02 
4 3 129.38 32.34±0.041 0.02 1.52 
5 4 173.79 43.45±0.031 0.03 2.03 
6 5 218.20 54.55±0.020 0.04 2.54 
7 6 262.61 65.65±0.081 0.04 2.94 
8 7 307.02 76.75±0.030 0.05 3.48 
9 8 351.43 87.86±0.051 0.06 4.09 
10 9 - - - - 
11 10 - - - - 
12 11 - - - - 
13 12 - - - - 
All the values are expressed as a mean  SD., n = 3 
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 Fig. 9.26.  Percentage drug release profile of formulation F7 
 Drug Release Profile for Formulation F8: 
Table 9.21: In vitro drug release data of Formulation F8 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N 
HCl 
0 0.00 0 0.00 0.00 
2 1 39.47 9.78 0.030 0.01 0.50 
3 2 82.80 20.70±0.041 0.01 1.02 
4 3 126.13 31.53±0.042 0.02 1.53 
5 4 169.45 42.36±0.020 0.03 2.08 
6 5 212.78 53.20±0.010 0.03 2.55 
7 6 256.12 64.03±0.031 0.04 3.07 
8 7 299.44 74.86±0.031 0.05 3.48 
9 8 342.76 85.69±0.021 0.06 3.99 
10 9 - - - - 
11 10 - - - - 
12 11 - - - - 
13 12 - - - - 
All the values are expressed as a mean  SD., n = 3 
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Fig. 9.27:  Percentage drug release profile of formulation F8 
 Drug Release Profile for Formulation F9: 
                         Table 9.22: In vitro Drug release data for formulation F9 
Sl. 
No. 
Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N 
HCl 
0 0.00 0 0.00 0.00 
2 1 38.93 09.73 0.051 0.01 0.50 
3 2 81.72 20.31±0.012 0.01 1.02 
4 3 124.51 31.46±0.041 0.02 1.54 
5 4 167.29 42.23±0.022 0.03 2.04 
6 5 210.75 53.50±0.021 0.03 2.56 
7 6 252.82 64.21±0.030 0.04 3.05 
8 7 295.65 73.92±0.033 0.05 3.50 
9 8 338.43 84.61±0.050 0.06 4.01 
10 9 - - - - 
11 10 - - - - 
12 11 - - - - 
13 12 - - - - 
           
All the values are expressed as a mean  SD., n = 3 
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                          Fig 9.28: Percentage drug release of formulation F9 
 In-vitro dissolution studies of all the formulation of Ofloxacin intragastric tablets 
were carried out in 0.1 N HCl. The study was performed for 12 hrs and cumulative drug 
release was calculated at different time interval. 
          This showed that HPMC hydrated more rapidly with high amount of SLS in the 
presence of 0.1 N HCl. The formulation F1, F2 and F3 showed the drug release 99.12, 
96.52 and 94.91% upto 12 hrs but F4, F5 and F6 showed the drug release 92.12, 90.06 
and 89.80% upto 10 hrs and F7, F8 and F9 showed the drug release 87.81, 85.64 and 
84.61 upto 8hrs. 
      The comparison graph for all formulations F1-F9 are also shown in following Fig 
9.30 
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              Fig 9.29: Comparison of percentage drug release of formulations F7, F8, F9 
 
          Fig. 9.30:  percentage drug release profile of formulation F1 – F9 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12
P
e
rc
e
n
ta
ge
 d
ru
g 
re
le
as
e
Time (Hours)
F7
F8
F9
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12
P
e
rc
e
n
ta
ge
  D
ru
g 
re
le
as
e
Time (Hours)
F1
F2
F3
F4
F5
F6
F7
F8
F9
Intragastric drug delivery system of Ofloxacin                                Results and Discussion             
 
Adhiparasakthi college of pharmacy, Melmaruvathur.  112 
 
9.4.3.2.Kinetics of In-vitro Drug Release:  
 Table 9.23: Different Kinetic models for Formulations F1-F9 
Code 
Zero order  First order Higuchi 
Korsemayer-
Peppas Best 
fit 
model R
2
 
K0 
(mg/h
−1
) 
R
2
 
K1 
(h
-1
) 
R
2
 
K  
(mg 
h
−1/2
) 
R
2
 n 
F1 0.9999 0.0100 0.9999 0.0001 0.9237 0.025 0.9999 1.0356 Peppas 
F2 
0.9999 0.0102 0.9999 0.0001 0.9236 0.0220 0.9999 1.0367 
Peppas 
F3 
0.9999 0.0103 0.9999 0.0001 0.9233 0.0290 0.9999 1.0347 
Peppas 
F4 0.9999 0.0120 0.9999 0.0001 0.9259 0.0310 0.9999 1.0346 Peppas 
F5 0.9998 0.0117 0.9998 0.0001 0.9266 0.0304 0.9998 1.0367 Peppas 
F6 0.9994 0.0118 0.9994 0.0001 0.9226 0.0305 0.9999 1.0413 Peppas 
F7 0.9996 0.0141 0.9996 0.0001 0.9304 0.0328 0.9997 1.0220 Peppas 
F8 0.9997 0.0141 0.9997 0.0001 0.9308 0.0328 0.9997 1.0422 Peppas 
F9 0.9998 0.0138 0.9998 0.0001 0.9302 0.0322 0.9999 1.0367 Peppas 
 
 
 
Fig. 9.31: Peppas plot of formulation F1 
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Fig. 9.32: Peppas plot of formulation F2 
 
 
Fig. 9.33: Peppas plot of formulation F3 
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Fig. 9.34: Peppas plot of formulation F4 
 
 
Fig. 9.35: Peppas plot of formulation F5 
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Fig. 9.36: Peppas plot of formulation F6 
 
 
Fig. 9.37: Peppas plot of formulation F7 
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Fig. 9.38: Peppas plot of formulation F8 
  
 
Fig9.39: Peppas plot of formulation F9 
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mechanism of drug transport, Fickian diffusion and a case-II transport, for the description 
of drug release from a swelling polymer. 
9.5. STABILITY STUDIES 
 From the results it was found that formulation F1 is the best formulation amongst the 
nine formulations. Thus formulation F1 was selected for stability studies.  
9.5.1. Stability studies at the end of First month (30 days): 
9.5.1.1. Hardness:  
 The hardness of tablet after one month of stability studies was studied. The 
results are within the limits. The data is shown in Table 9.24. 
Table 9.24: Hardness of formulation F1 at the end of one month of stability 
All the values are expressed as a mean  SD., n = 6 
9.5.1.2. Drug Content :  
  The Percentage drug content of tablet after one month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 9.25. 
       Table 9.25: Drug content of formulation F1 at the end of one month of stability 
Sl. No. Formulation Percentage drug content 
1. F1 99.12  0.060 
All the values are expressed as a mean  SD., n = 3 
9.5.1.3. In vitro Buoyancy Studies: 
 
Sl. No. Formulation Hardness (kg/cm
2
) 
1. F1 3.42  0.032 
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9.5.1.3.1. Floating lag time: 
 The floating lag time of tablet after one month of stability studies was studied. 
The data was shown in the table 9.26 
Table 9.26: Floating lag time of formulation F1 after one month stability 
 Sl.No           Formulation               Floating lag time 
     1.                  F1                     36.46±0.036 
                                                                                                                            
9.5.1.3.2.  Total Floating time: 
  The total floating time of tablet after one month study of stability was studied. It 
was found to be more than(>) 12 hrs. 
9.5.1.4. In vitro drug release study:  
  The percentage drug release from F1 tablet after one month of stability was 
studied. The data is shown in Table 9.27. 
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Table 9.27:  In vitro drug release data of formulation F1 at the end of one month of 
stability 
Sl. 
No. 
Medium 
Time 
(hours) 
Amount of 
drug 
released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N 
HCl 
0 0 0 0 0 
2 1 1.15 07.33 0.18 0.01 0.50 
3 2 2.48 15.67 0.040 0.01 1.02 
4 3 3.81 24.01 0.032 0.02 1.52 
5 4 5.14 32.35 0.045 0.02 2.03 
6 5 6.47 40.69 0.051 0.03 2.54 
7 6 7.80 48.89 0.045 0.03 2.94 
8 7 9.13 57.37 0.030 0.04 3.40 
9 8 10.46 65.71 0.060 0.04 4.09 
10 9 11.79 74.05 0.030 0.05 4.82 
11 10 13.12 82.39 0.055 0.05 5.05 
12 11 14.45 90.73 0.030 0.06 5.94 
13 12 15.78 99.07 0.032 0.06 6.02 
 
All the values are expressed as a mean  SD., n = 3 
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Fig. 9.40:  In vitro drug release profile of formulation F1 at the end of 1 month of 
stability 
9.5.2. Stability studies at the end of Second month (60 days): 
9.5.2.1. Hardness:  
 The hardness of tablet after Two months of stability studies was studied. The 
results are within the limits. The data is shown in Table 9.28. 
     Table 9.28:  Hardness of formulation F1 at the end of two months of stability 
Sl. No. Formulation Hardness (kg/cm
2
) 
1. F1 3.40  0.095 
All the values are expressed as a mean  SD., n = 3 
9.5.2.2. Drug content:  
  The Percentage drug content of tablet after Two months of stability studies was 
studied. The results are within the official limits. The data is shown in Table 9.29. 
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Table 9.29: Drug content of formulation F1 at the end of two months of stability 
Sl. No. Formulation Percentage drug content 
1. F1 99.10 0.030  
All the values are expressed as a mean  SD., n = 3 
9.5.2.3.In vitro Buoyancy Studies: 
9.5.2.4. 1 Floating lag time: 
 The floating lag time of tablet after two months of stability studies was studied. 
The data was shown in the table 9.30 
Table 9.30: Floating lag time of formulation F1 after two months stability 
 Sl.No           Formulation               Floating lag time 
     1.                  F1                     36.39±0.005 
                                                                                                                            
9.5.2.3.2.  Total Floating time: 
 The total floating time of tablet after two months study of stability was studied. It 
was found to be more than(>) 12 hrs. 
9.5.2.4. In vitro dissolution study:  
 The Percentage Drug Release from F2 tablet after Two months of stability was 
studied. The data is shown in Table 9.31. 
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Table 9.31: In vitro drug release data of formulation F1 at the end of two months of 
stability 
\Sl. 
No. 
Medium 
Time 
(hours) 
Amount of 
drug released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N HCl 
0 0.00 0 0.00 0.00 
2 1 1.12 7.30 0.026 0.01 0.50 
3 2 2.45 15.64 0.030 0.01 1.02 
4 3 3.57 23.98 0.045 0.02 1.52. 
5 4 4.90 32.32 0.015 0.02 2.03 
6 5 6.23 40.66 0.037 0.03 2.54 
7 6 7.56 49.00 0.030 0.03 2.94 
8 7 8.89 57.34 0.045 0.04 3.48 
9 8 10.22 65.68 0.040 0.04 4.09 
10 9 11.55 74.02 0.056 0.05 4.82 
11 10 12.88 82.36 0.035 0.05 5.02 
12 11 14.21 90.70 0.015 0.06 5.92 
13 12 15.54 99.04 0.025 0.06 6.06 
                       
All the values are expressed as a mean  SD., n = 3 
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Fig. 9.41: In vitro Drug release profile of formulation F1 at the end of 2 months of 
stability 
 
9.5.3. Stability studies at the end of Three months (90 days): 
9.5.3.1.Hardness:  
 The hardness of tablet after Three months of stability studies was studied. The 
results are within the limits. The data is shown in Table 9.32. 
Table 9.32: Hardness of formulation F1 at the end of three months of stability 
Sl. No. Formulation Hardness (kg/cm
2
) 
1. F1 3.39 0.035  
 
All the values are expressed as a mean  SD., n = 3 
9.5.3.2.Drug content:  
  The Percentage drug content of tablet after Third month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 9.33. 
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Table 9.33: Drug content of formulation F1 at the end of three months of stability 
 Sl. No. Formulation Percentage drug content 
1. F1 99.08 0.031  
 
All the values are expressed as a mean  SD., n = 3 
9.5.3.3. In vitro Buoyancy Studies: 
9.5.3.3.1.  Floating lag time: 
 The floating lag time of tablet after three months of stability studies was studied. 
The data was shown in the table 9.34 
Table 9.34: Floating lag time of formulation F1 after three months stability 
 Sl.No           Formulation               Floating lag time 
     1.                  F1                     36.00±0.005 
                                                                                                                            
9.5.3.3.2 Total Floating time: 
 The total floating time of tablet after three months study of stability was studied.  
 It was found to be more than(>) 12 hrs. 
9.5.3.4. In vitro Drug Release study:  
  The  Percentage Drug Release from F1 tablet after three months of stability was 
studied. The data is shown in Table 9.35. 
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Table 9.35: In vitro drug release data of formulation F1 at the end of three months of 
stability 
Sl. No. Medium 
Time 
(hours) 
Amount of 
drug released 
(mg) 
% Drug 
Release %DE 
MDT 
(hrs) 
1 
0.1N HCl 
0 0.00 0 0.00 0.00 
2 1 1.08 7.27±0.035 0.01 0.50 
3 2 2.42 15.60±0.036 0.01 1.02 
4 3 3.76 23.94±0.026 0.02 1.52 
5 4 5.10 32.28±0.030 0.02 2.03 
6 5 6.44 40.62±0.040 0.03 2.54 
7 6 7.78 48.96±0.030 0.03 2.94 
8 7 9.12 57.30±0.040 0.04 3.48 
9 8 10.46 65.64±0.025 0.04 4.09 
10 9 11.80 73.98±0.030 0.05 4.82 
11 10 13.14 82.32±0.028 0.05 5.01 
12 11 14.48 90.66±0.045 0.06 5.34 
13 12 
15.82 99.00±0.030 0.06 6.02 
 
All the values are expressed as a mean  SD., n = 3 
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Fig. 9.42: In vitro drug release profile of formulation F1 at the end of 3 months of 
stability 
 
 
 
 
Fig 9.43: Floating lag time of F1 after stability studies for 3 months 
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Fig. 9.44: Comparisons of percentage drug content for formulation F1 with initial and 
different periods of stability 
 
        No statistically significant differences were observed in Hardness, percentage drug 
content and  percentage drug release in optimized formulation at the end of three months 
of stability studies. 
So, it can be concluded that the formulation is stable for short term storage 
conditions. 
99.2 99.12 99.10 99.08
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Initial First month Second month Third month
P
e
rc
e
n
ta
ge
 d
ru
g 
re
le
as
e
Months
Initial
First month
Second month
Third month
  
 
 
 
 
 
 
SUMMARY  
& 
CONCLUSION 
Intragastric drug delivery system of Ofloxacin                            Summary and Conclusion             
 
Adhiparasakthi college of pharmacy, Melmaruvathur 128 
 
                      
                                                                                                                              10. SUMMARY AND CONCLUSION 
 
The formulation development and in-vitro evaluation of gastroretentive floating 
drug delivery system of ofloxacin tablets was performed in the present study. The 
formulation development of intragastric floating  drug delivery system of Ofloxacin in 
the form of tablets was performed by using 3
2
 full factorial method with polymers HPMC 
K15, HPMC K100 and SLS. 
           Preformulation study was carried out for powder blends, it was evaluated to 
determine the flow characteristics by angle of repose, bulk density, tapped density, carr’s 
index and Hausner’s ratio. The data obtained from these studies indicated that the powder 
blends had good flow properties. 
            The tablets were prepared with different ratios of polymers by direct compression 
technique. The formulated tablets were evaluated for physical characterization like 
thickness, hardness, friability, weight variation and drug content. All the physical 
parameters of prepared tablets compiles with IP specifications. 
           Evaluation studies of all formulations showed that the drug content, weight 
variation and friability as per the standards given in IP. The hardness of all formulations 
was within the limits. 
           The swelling index of the tablets of the tablets from each formulation was 
evaluated. The highest swelling was observed with the formulation F1. The amount of 
water uptake may be due to quick hydration of polymers. 
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           The in-vitro dissolution study closely indicates that among nine formulations the 
formulation F1 showed high percentage of drug release and it is considered as the best 
formulation. 
            The regression correlation co-efficient value was concluded in kinetics modeling 
of drug dissolution profile for all formulations. The formulation F1 was found to be best 
fit model following peppas drug release. 
             From the stability data, it can be concluded that there was no significant changes 
in any parameters. Hence, the formulation F1 is considered to be highly stable 
formulation. 
            The overall studies indicate that polymers HPMC K15 and HPMC K100 and SLS 
(2%) showed satisfactory gastro retentive properties. Among the nine formulations the 
formulation F1exhibited optimum drug release profile. 
            Hence, it is concluded that the formulation  F1 will be useful for preparing 
gastroretentive drug delivery system of Ofloxacin. 
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11. FUTURE PROSPECTS 
 
               In the present work floating tablets of Ofloxacin were formulated using 
synthetic polymers by direct compression method. In this work only physicochemical 
characterization, formulation and in-vitro evaluation of floating tablets of Ofloxacin was 
done. Along with in-vitro release study in-vivo release behavior of drug is also important. 
So in future in-vivo release study using different models are required to set the in-vitro 
in-vivo correlation which is necessary for development of successful formulation and 
also long term stability studies are necessary. 
              Convincing results for clinical studies have yet to be obtained for a 
gastroretentive system that displays the necessary performance behavior and which is 
retained in the fasted stomach of humans for a sensible period of time after dosing. 
Furthermore, the system will need to retain its integrity for an extended period of time in 
the harsh conditions present in the human stomach. 
            The control of GI transit profiles could be focus of the next two decades and 
might result in the availability of new products with new therapeutic possibilities and 
substantial benefits for patients. 
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